var data={"title":"Free-living amebas and Prototheca","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Free-living amebas and Prototheca</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/contributors\" class=\"contributor contributor_credentials\">Carlos Seas, MD, FIDSA</a></dd><dd><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/contributors\" class=\"contributor contributor_credentials\">Francisco Bravo, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/contributors\" class=\"contributor contributor_credentials\">Peter F Weller, MD, MACP</a></dd><dd><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/contributors\" class=\"contributor contributor_credentials\">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 09, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H13571641\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Free-living amebas are environmental protozoan parasites with worldwide distribution. They exist in nature without the need for a host; they are not well adapted to parasitism and do not require a vector for transmission to humans or animals [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Four genera of amebas cause disease in humans: <em>Naegleria</em> (only <em>N. fowleri</em>), <em>Acanthamoeba</em> (several species), <em>Balamuthia</em> (only <em>B. mandrillaris</em>), and <em>Sappinia</em> (only <em>S. pedata</em>) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/2,3\" class=\"abstract_t\">2,3</a>]. All of these species cause central nervous system (CNS) infections; several species of <em>Acanthamoeba</em> may cause localized extra-CNS infections in immunocompetent hosts or disseminated infections in immunocompromised hosts.</p><p>Members of the genus <em>Prototheca</em> are also environmental pathogens that are rare causes of human infection; <em>Prototheca</em> are classified as green algae, which are unicellular eukaryotes that do not have <a href=\"topic.htm?path=chlorophyll-drug-information\" class=\"drug drug_general\">chlorophyll</a>.</p><p>Issues related to infections caused by free-living amebas and members of the genus <em>Prototheca</em> will be reviewed here.</p><p class=\"headingAnchor\" id=\"H13571648\"><span class=\"h1\">CENTRAL NERVOUS SYSTEM INFECTIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Two distinctive clinical syndromes associated with free-living amebas are well recognized: primary amebic meningoencephalitis (PAM) and granulomatous amebic encephalitis (GAE).</p><p class=\"headingAnchor\" id=\"H13571655\"><span class=\"h2\">Primary amebic meningoencephalitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PAM is an acute hemorrhagic meningoencephalitis caused by <em>N. fowleri.</em> It<em> </em>is characterized by a fulminant course with clinical and laboratory features that resemble acute bacterial meningitis.</p><p class=\"headingAnchor\" id=\"H4971137\"><span class=\"h3\">Naegleria fowleri</span></p><p class=\"headingAnchor\" id=\"H13571662\"><span class=\"h4\">Epidemiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>N. fowleri</em> is a thermophilic ameboflagellate protozoan parasite globally distributed in water and soil that lives in temperatures above 30&deg;C and tolerates temperatures up to 45&deg;C. The life cycle of <em>N. fowleri</em> includes three stages: the infective trophozoite, a transient non-dividing flagellate stage, and the cystic stage (<a href=\"image.htm?imageKey=ID%2F53111\" class=\"graphic graphic_figure graphicRef53111 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/4\" class=\"abstract_t\">4</a>].</p><p><em>N. fowleri</em> has been isolated from a variety of fresh- and warm water sources worldwide (lakes, ponds, rivers, streams, irrigation canals, hot springs, unchlorinated swimming pools, spas, aquaria, and sewage) but not from seawater [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/1,5,6\" class=\"abstract_t\">1,5,6</a>]. History of recreational water activities is the most common risk factor for infection [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/1,7\" class=\"abstract_t\">1,7</a>]. Activities such as swimming, diving, jumping, splashing, use of watercrafts, waterskiing, surfing, exposure to hot springs, and facial contact with mud have been reported in PAM cases [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/8\" class=\"abstract_t\">8</a>]. Isolation of the ameba in the environment where cases have occurred is common [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/9\" class=\"abstract_t\">9</a>]. Tap water exposures [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/10\" class=\"abstract_t\">10</a>], including during ritual purification and nasal irrigation [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/11-13\" class=\"abstract_t\">11-13</a>], have also been described. Asymptomatic children and patients with PAM may harbor the ameba in the nasal mucosa [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/14\" class=\"abstract_t\">14</a>]. There is concern that global warming and changes in the ecosystems <em>N. fowleri</em> inhabit may lead to more cases worldwide [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/11,15\" class=\"abstract_t\">11,15</a>].</p><p>PAM was initially reported in Australia in 1965; since then, it has been reported in more than 16 countries [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/16\" class=\"abstract_t\">16</a>]. The total number of cases is unknown; it is estimated that approximately 300 cases have occurred worldwide. The largest series of well-documented PAM cases comes from the United States, in which 111 PAM cases were reported. The mean patient age was 12 years (range 8 months to 66 years); 79 percent were males, and 62 percent were children. No evidence of immunosuppression was identified, and 87 percent of cases occurred during the summer [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/16\" class=\"abstract_t\">16</a>]. Water exposure occurred in 81 percent of cases, including exposure to lakes and ponds in 74 percent. No clear source was identified in 19 percent of cases.</p><p>Exposure is more common than disease. There is a high prevalence of positive serology [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/17,18\" class=\"abstract_t\">17,18</a>], while the risk of infection is approximately 2.6 cases per million exposures [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/19\" class=\"abstract_t\">19</a>]. The reasons for the low prevalence of disease in humans despite frequent exposure are unknown.</p><p>Transmission to humans occurs primarily through inhalation of infested water. Activities that increase contact of the nasal mucosa with infested water predispose humans to infection. Trophozoites penetrate the olfactory mucosa, cross the cribriform plates, and ultimately reach the olfactory bulb. Water exposure in patients with tympanic membrane ruptures may also lead to PAM [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/20\" class=\"abstract_t\">20</a>]. Cases of infection with no clear history of exposure have also been reported [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/16\" class=\"abstract_t\">16</a>].</p><p>The risks and benefits should be weighed carefully when an organ from a patient with PAM is considered for transplantation. Thus far, acquisition of primary amebic encephalitis from solid organ transplantation has not been observed. In a comprehensive evaluation of 21 transplant recipients of solid organs donated by five patients who died of PAM, there was no evidence of PAM among the recipients [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/21\" class=\"abstract_t\">21</a>]. However, extra&ndash;central nervous system (CNS) dissemination of <em>N. fowleri</em> infection may occur and might pose a risk for disease transmission via transplantation [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/21\" class=\"abstract_t\">21</a>].</p><p class=\"headingAnchor\" id=\"H13571669\"><span class=\"h4\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PAM is an acute meningoencephalitis associated with an extremely high mortality rate. The case-fatality rate in one series including 111 cases was 99 percent [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/16\" class=\"abstract_t\">16</a>]. In that study, the mean incubation period was 5 days (range 1 to 7 days), the mean time from onset of symptoms to death was 5.3 days (range 1 to 12 days), and the mean time from exposure to death was 9.9 days (range 6 to 17 days). In another series including 142 patients in the United States (median age 12 years), only 27 percent were diagnosed pre-mortem; 3 patients survived [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/22\" class=\"abstract_t\">22</a>].</p><p>Common clinical manifestations include high fever, severe headache, photophobia, nausea, vomiting, behavioral abnormalities, seizures, and altered mental status. Smell and taste abnormalities may occur early and may reflect the migration of the organism through the olfactory mucosa. Physical examination demonstrates meningeal signs (Kerning and Brudzinski signs) and cranial nerve palsies indicating uncal herniation [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/2\" class=\"abstract_t\">2</a>]. The progression of the disease is very rapid, with profound mental alteration and severe cranial hypertension leading to herniation and death in a matter of few days. Cardiac involvement with arrhythmia has also been reported [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/2\" class=\"abstract_t\">2</a>].</p><p>Laboratory findings demonstrate leukocytosis with neutrophilia. Examination of the cerebrospinal fluid (CSF) demonstrates a yellowish-white to grayish color initially, which turns into frankly hemorrhagic fluid as the disease progresses [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/2\" class=\"abstract_t\">2</a>]. The CSF white blood cell count ranges from 300 to 26,000 cells per mm<sup>3</sup> with marked polymorphonuclear predominance; CSF red blood cells are usually seen, ranging from 250 to 24,600 cells per mm<sup>3</sup>. Glucose is usually markedly consumed in the CSF, and the protein concentration is usually elevated. CSF pressure is usually very high, ranging from 300 to 600 mmHg [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/2\" class=\"abstract_t\">2</a>]. Studies for bacterial pathogens are usually negative, including Gram stain and culture. However, secondary bacterial infections can be introduced by the ameba; this was illustrated in a report of <em>Burkholderia cepacia</em> (a soil-water transmitted pathogen) infection of the CSF in a patient with PAM [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/15\" class=\"abstract_t\">15</a>].</p><p class=\"headingAnchor\" id=\"H13571676\"><span class=\"h4\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinicians should have a high index of suspicion for PAM in the setting of acute meningoencephalitis with negative results for bacteria and common viruses, which should prompt the search for amebas in the CSF. History of exposure increases the likelihood of PAM, but it is not always obtained.</p><p>The diagnosis of PAM is generally established via observation of motile trophozoites on examination of a centrifuged CSF wet mount preparation immediately after obtaining the sample. A phase-contrast microscope is useful to optimize visualization of the ameba. Trophozoites tend to immobilize when exposed to diluted fluid and may resemble leukocytes. Giemsa or trichrome stains help in identifying morphologic features of the trophozoites: 10 to 25 microns in size with a single nucleus and a centrally located nucleolus with no peripheral chromatin (<a href=\"image.htm?imageKey=ID%2F87778\" class=\"graphic graphic_picture graphicRef87778 \">picture 1</a> and <a href=\"image.htm?imageKey=ID%2F58751\" class=\"graphic graphic_picture graphicRef58751 \">picture 2</a>) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/4\" class=\"abstract_t\">4</a>].</p><p>A multiplex polymerase chain reaction (PCR) facilitates for rapid detection; it can identify the DNA of the major free-living amebas in CSF in about five hours, although this diagnostic methodology is not widely available [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/23\" class=\"abstract_t\">23</a>]. <em>N. fowleri</em> can be isolated in non-nutrient agar coated with enteric bacteria. Serology is not useful for diagnosis.</p><p>Imaging findings on computed tomography (CT) and magnetic resonance imaging (MRI) are nonspecific. Brain edema, basilar meningeal enhancement, hydrocephalus, and areas of cerebral infarction have been described (<a href=\"image.htm?imageKey=ID%2F87779\" class=\"graphic graphic_diagnosticimage graphicRef87779 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/24\" class=\"abstract_t\">24</a>]. Lesions in the brain tend to be located in the orbitofrontal and temporal lobes, base of the brain, cerebellum, and upper spinal cord [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/25\" class=\"abstract_t\">25</a>]. A purulent exudative inflammation along the leptomeninges and extensive necrosis and hemorrhage of the parenchyma are characteristic pathological findings (<a href=\"image.htm?imageKey=GAST%2F87780\" class=\"graphic graphic_picture graphicRef87780 \">picture 3</a>) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/26\" class=\"abstract_t\">26</a>].</p><p>Brain tissue can be examined for trophozoites, and brain sections can be stained with immunofluorescent anti&ndash;<em>N. fowleri</em> antibodies [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/27\" class=\"abstract_t\">27</a>].</p><p class=\"headingAnchor\" id=\"H1746433426\"><span class=\"h4\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PAM must be distinguished from acute bacterial meningitis. The clinical manifestations and CSF findings of these two entities are similar. Epidemiological exposure may be useful in differentiating the two conditions. In general, patients with PAM receive treatment for bacterial meningitis before the definitive diagnosis is established. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-acute-bacterial-meningitis-in-adults\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of acute bacterial meningitis in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H13571683\"><span class=\"h4\">Treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal approach to treatment of PAM due to <em>N. fowleri </em>is uncertain; no studies evaluating the efficacy of single-drug or combination-drug regimens have been performed [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/28\" class=\"abstract_t\">28</a>]. The rarity of the disease, delay in diagnosis, fulminant clinical course, and the difficulties in making a rapid diagnosis have hampered the evaluation of drug regimens. In theory, the best drug regimen should include an amebicidal drug (or a combination of drugs) with good in vitro activity that is capable of crossing the blood-brain barrier.</p><p>Based on articles published following well-documented survivors as well as extrapolation from experience with treatment of infection due to <em>Acanthamoeba</em> and <em>Balamuthia</em> infection, we suggest the following combination of drugs (in addition to steroids to control cerebral edema) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/2,29-31\" class=\"abstract_t\">2,29-31</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Conventional amphotericin B (1.5 <span class=\"nowrap\">mg/kg/day</span> intravenously [IV] <span class=\"nowrap\">+/-</span> intrathecally)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> (rifampicin; 10 <span class=\"nowrap\">mg/kg/day</span> orally in three divided doses or every 24 hours)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">Fluconazole</a> (10 <span class=\"nowrap\">mg/kg/day</span> IV or orally)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Miltefosine</a> (&lt;45 kg: 50 mg orally twice daily; &ge;45 kg: 50 mg orally three times daily)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">Azithromycin</a> (500 mg IV or orally)</p><p/><p>The optimal duration of therapy is uncertain; reports range from 9 to 30 days.</p><p><a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">Amphotericin B deoxycholate</a> demonstrates the most favorable in vitro activity (with minimum inhibitory concentrations [MICs] in the range of 0.026 to 0.078 <span class=\"nowrap\">mcg/mL)</span> and is considered the drug of choice. Administration of amphotericin B is warranted as soon as the diagnosis is considered [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/32\" class=\"abstract_t\">32</a>]. <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">Liposomal amphotericin B</a> is less effective in animal models and has higher MICs than the conventional preparation [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/33-35\" class=\"abstract_t\">33-35</a>].</p><p>Other active drugs in vitro include the azoles (<a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, <a href=\"topic.htm?path=miconazole-drug-information\" class=\"drug drug_general\">miconazole</a>, <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a>, and <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>), rifampicin, <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a>, <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a>, <a href=\"topic.htm?path=chlorpromazine-drug-information\" class=\"drug drug_general\">chlorpromazine</a>, and <a href=\"topic.htm?path=chloramphenicol-drug-information\" class=\"drug drug_general\">chloramphenicol</a> [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/4\" class=\"abstract_t\">4</a>]. The in vitro activity of rifampicin is uncertain [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/29\" class=\"abstract_t\">29</a>]. Variations in virulence factors and sensitivity to antimicrobials have been postulated to explain clinical outcomes [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/28\" class=\"abstract_t\">28</a>].</p><p>Approximately 11 survivors of PAM are reported in the literature [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/11,28,30,36,37\" class=\"abstract_t\">11,28,30,36,37</a>]. In most of these cases, an early diagnosis was made, and treatment with amphotericin B was initiated promptly; the most frequently used regimen was amphotericin B plus rifampicin (10 <span class=\"nowrap\">mg/kg/day)</span>. Synergy of amphotericin B with azoles (<a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> 10 <span class=\"nowrap\">mg/kg/day)</span> and <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> has also been described. In one case, intrathecal administration of amphotericin B and <a href=\"topic.htm?path=miconazole-drug-information\" class=\"drug drug_general\">miconazole</a> was used [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/29\" class=\"abstract_t\">29</a>].</p><p>The use of <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> for treatment of PAM has been extrapolated from favorable clinical experience with its use in the treatment of <em>Balamuthia mandrillaris</em> and <em>Acanthamoeba</em> spp infections [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/38\" class=\"abstract_t\">38</a>]. (See <a href=\"#H13571697\" class=\"local\">'Acanthamoeba'</a> below and <a href=\"#H13571732\" class=\"local\">'Balamuthia mandrillaris'</a> below.)</p><p><a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">Azithromycin</a> has both animal and in vitro efficacy against <em>N. fowleri</em> and appears to be synergistic when administered with amphotericin B [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/34,39\" class=\"abstract_t\">34,39</a>].</p><p class=\"headingAnchor\" id=\"H13571690\"><span class=\"h2\">Granulomatous amebic encephalitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>GAE is a rare subacute-chronic infection of the CNS caused by <em>Acanthamoeba</em> species, <em>B. mandrillaris,</em> and <em>S. pedata</em>.</p><p class=\"headingAnchor\" id=\"H13571697\"><span class=\"h3\">Acanthamoeba</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Acanthamoeba</em> is the most common ameba found in nature and largely causes opportunistic infections in immunocompromised hosts. Predisposing conditions include diabetes, alcoholism, cirrhosis, HIV infection, chronic renal failure, systemic lupus, malignancy, chemotherapy, and organ transplantation including hematopoietic stem cell transplantation (mostly allogenic transplant recipients but also solid organ transplantation) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/40,41\" class=\"abstract_t\">40,41</a>]. Of more than 150 cases of GAE reported in the literature, 11 have been in immunocompetent hosts [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/42\" class=\"abstract_t\">42</a>]. No cases of GAE acquired by solid organ transplantation have been described.</p><p class=\"headingAnchor\" id=\"H13571704\"><span class=\"h4\">Epidemiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Acanthamoeba</em> can be found in soil (beach sands, flowerpot soil), air, and in a number of water environments rich in biofilms (brackish water, sewage, humidifiers, heating hospital environments, dental and dialysis units, contact lenses) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/5\" class=\"abstract_t\">5</a>]. Modes of transmission include inhalation of cysts carried by wind through the respiratory tract or direct skin contact followed by hematogenous spread [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/1\" class=\"abstract_t\">1</a>]. No seasonality has been reported, and usually no history of water or soil exposure is elicited from GAE patients [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/4\" class=\"abstract_t\">4</a>]. <em>Acanthamoeba</em> have been found in the nasal mucosa of both patients and asymptomatic individuals, suggesting a nasal route of spread [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/2,4\" class=\"abstract_t\">2,4</a>].</p><p>The <em>Acanthamoeba </em>life cycle includes two stages: a vegetative trophozoite and a cyst (<a href=\"image.htm?imageKey=ID%2F70542\" class=\"graphic graphic_figure graphicRef70542 \">figure 2</a>). Seventeen different genotypes have been identified, from T1 to T17; the majority of human cases are associated with the genotype T4, followed by genotypes T1, T10, and T12 [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/42\" class=\"abstract_t\">42</a>]. A unique case associated with genotype T2 in an HIV-infected patient has also been reported [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/43\" class=\"abstract_t\">43</a>].</p><p>Other infections can occur simultaneously with <em>Acanthamoeba</em>, including <em>Legionella</em> spp, <em>Vibrio cholerae</em>, <em>B. cepacia</em>, <em>Listeria</em> <em>monocytogenes</em>, and <em>Mycobacterium</em> spp [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/5,44\" class=\"abstract_t\">5,44</a>]. A fatal case of multiple protozoan infections (<em>Acanthamoeba </em>spp, <em>B. mandrillaris</em>, and <em>Toxoplasma gondii</em>) in an HIV-infected patient has also been reported [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/45\" class=\"abstract_t\">45</a>].</p><p class=\"headingAnchor\" id=\"H13571711\"><span class=\"h4\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>GAE consists of a prolonged clinical course characterized by weeks or months of worsening headache, low-grade fever, visual disturbances, behavioral abnormalities, and focal neurologic deficits depending on the topographic location of lesions [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/2\" class=\"abstract_t\">2</a>]. The incubation period is usually not known as it is often difficult to determine when exposure took place. As the disease progresses, intracranial pressure, seizures, loss of consciousness, coma, and death ensue.</p><p>Lumbar puncture is generally contraindicated for patients who present with a focal lesion associated with elevated intracranial pressure. For patients in whom the CSF can be obtained, nonspecific findings are observed, including mild pleocytosis with lymphocytic predominance, high protein concentration, and low or normal glucose concentration [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/46\" class=\"abstract_t\">46</a>]. <em>Acanthamoeba</em> trophozoites are seldom seen in a CSF sample [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/1\" class=\"abstract_t\">1</a>], but Giemsa stain of the CSF sediment may demonstrate trophozoites [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/47\" class=\"abstract_t\">47</a>].</p><p class=\"headingAnchor\" id=\"H3212527470\"><span class=\"h4\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Brain tissue is needed to confirm the diagnosis. Staining with hematoxylin-eosin demonstrates both trophozoites and cysts. Trophozoites are seen in the perivascular space; their size is 15 to 30 microns, and they have a large nucleolus with a centrally located nucleolus (<a href=\"image.htm?imageKey=ID%2F64215\" class=\"graphic graphic_picture graphicRef64215 \">picture 4</a>) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/46\" class=\"abstract_t\">46</a>]. Thick-walled cysts (10 to 25 microns usually with a double layer) can be seen in tissue sections (<a href=\"image.htm?imageKey=ID%2F87781\" class=\"graphic graphic_picture graphicRef87781 \">picture 5</a>). In patients with concomitant skin or pulmonary lesions, tissue samples from these organs may also demonstrate trophozoites [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/48\" class=\"abstract_t\">48</a>]. Indirect immunofluorescence and immunoperoxidase stains are helpful for identifying <em>Acanthamoeba</em> in brain and other tissues [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/46,49\" class=\"abstract_t\">46,49</a>].</p><p>Tissue samples can be cultured in non-nutrient agar coated by enteric bacteria [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/4\" class=\"abstract_t\">4</a>]. PCR methods applied to brain or other tissues provide a more rapid diagnosis; however, availability of these methods is limited [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/23,50\" class=\"abstract_t\">23,50</a>].</p><p>Brain CT scans and MRI show single or multiple space-occupying lesions with ring enhancement (<a href=\"image.htm?imageKey=RADIOL%2F85823\" class=\"graphic graphic_diagnosticimage graphicRef85823 \">image 2</a>) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/51\" class=\"abstract_t\">51</a>]. Temporal and parietal lobes are most commonly affected.</p><p>Postmortem examination of the brain demonstrates significant edema and multiple hemorrhagic areas [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/4\" class=\"abstract_t\">4</a>]. Microscopic examination reveals extensive necrosis and the presence of multinucleated giant cells. Granulomas can be seen in immunocompetent patients, and an abundance of both trophozoites and cysts located in perivascular areas are characteristic findings (<a href=\"image.htm?imageKey=ID%2F88021\" class=\"graphic graphic_picture graphicRef88021 \">picture 6</a>) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/4\" class=\"abstract_t\">4</a>].</p><p class=\"headingAnchor\" id=\"H1746433471\"><span class=\"h4\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of GAE is broad and includes pathogens that cause focal neurologic lesions in immunosuppressed patients. Brain biopsy is needed to establish the diagnosis of GAE. The differential diagnosis includes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tuberculosis &ndash; Clinical manifestations of CNS tuberculosis include seizure or headache; occasionally, hemiplegia or signs of raised intracranial pressure are observed. Diagnostic tools include CSF examination and radiography. (See <a href=\"topic.htm?path=central-nervous-system-tuberculosis\" class=\"medical medical_review\">&quot;Central nervous system tuberculosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nocardiosis &ndash; CNS nocardiosis consists of parenchymal abscess that can occur in any region of the brain. Signs and symptoms are nonspecific; they may include fever, headache, meningismus, seizure, <span class=\"nowrap\">and/or</span> focal neurologic deficits. The diagnosis requires isolation of the organism from a clinical specimen. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-nocardiosis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of nocardiosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bacterial brain abscess &ndash; Clinical manifestations of brain abscess may include headache, focal neurologic deficits, and seizures. The diagnosis consists of imaging (MRI or CT) and lumbar puncture in the absence of mass effect. (See <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-brain-abscess\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of brain abscess&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aspergillosis &ndash; CNS aspergillosis may occur in the setting of local extension of disease from the paranasal sinuses or via disseminated infection. Clinical manifestations include seizures or focal neurologic signs. Imaging findings include ring-enhancing lesions or cerebral infarction. Confirmation of the diagnosis requires biopsy. (See <a href=\"topic.htm?path=epidemiology-and-clinical-manifestations-of-invasive-aspergillosis\" class=\"medical medical_review\">&quot;Epidemiology and clinical manifestations of invasive aspergillosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cryptococcosis &ndash; Clinical manifestations of cryptococcal meningoencephalitis may be acute or chronic and may include fever, headache, lethargy, and altered mental status. A lumbar puncture is necessary to establish the diagnosis. (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in HIV-infected patients&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Histoplasmosis &ndash; Clinical manifestations of CNS histoplasmosis include headache, altered mental status, and cranial nerve deficits. CSF examination demonstrates pleocytosis with a preponderance of lymphocytes; histopathology characteristically demonstrates granulomatous inflammation. (See <a href=\"topic.htm?path=diagnosis-and-treatment-of-disseminated-histoplasmosis-in-hiv-uninfected-patients\" class=\"medical medical_review\">&quot;Diagnosis and treatment of disseminated histoplasmosis in HIV-uninfected patients&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Toxoplasmosis &ndash; Clinical manifestations of toxoplasmosis include headache, altered mental status, and confusion. The diagnosis is established via detection of the organism in a biopsy specimen. (See <a href=\"topic.htm?path=toxoplasmosis-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Toxoplasmosis in HIV-infected patients&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cysticercosis &ndash; Clinical manifestations of cysticercosis include seizures and headache. The diagnosis is largely based on clinical presentation and radiographic imaging. (See <a href=\"topic.htm?path=cysticercosis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Cysticercosis: Clinical manifestations and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary CNS lymphoma &ndash; Clinical manifestations of primary CNS lymphoma include focal neurologic deficits, neuropsychiatric symptoms, and signs of elevated intracranial pressure. The diagnosis is established via biopsy. (See <a href=\"topic.htm?path=clinical-presentation-pathologic-features-and-diagnosis-of-primary-central-nervous-system-lymphoma\" class=\"medical medical_review\">&quot;Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Balamuthia</em> encephalitis &ndash; Clinical manifestations of <em>Balamuthia</em> encephalitis include fever, headache, seizure, cranial nerve dysfunction, or localized motor deficits. The diagnosis is established via brain biopsy. (See <a href=\"#H13571732\" class=\"local\">'Balamuthia mandrillaris'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H13571725\"><span class=\"h4\">Treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal approach to treatment is uncertain [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/52\" class=\"abstract_t\">52</a>]; therefore, combination regimens are preferred over single-drug regimens. We favor empiric treatment with a combination of <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a>, <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, and <a href=\"topic.htm?path=pentamidine-drug-information\" class=\"drug drug_general\">pentamidine</a> isethionate. <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">Trimethoprim-sulfamethoxazole</a>, <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>, and a macrolide (<a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> or <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a>) can be added to this regimen as well.</p><p>A number of drugs have in vitro activity and have resulted in success for a few patients when used alone or in combination: rifampicin, azoles (<a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>), <a href=\"topic.htm?path=pentamidine-drug-information\" class=\"drug drug_general\">pentamidine</a> isethionate, <a href=\"topic.htm?path=sulfadiazine-drug-information\" class=\"drug drug_general\">sulfadiazine</a>, <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">flucytosine</a>, <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a>, <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a>, and <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/46,53-60\" class=\"abstract_t\">46,53-60</a>]. Variations in susceptibility and virulence may account for poor clinical responses [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/28\" class=\"abstract_t\">28</a>].</p><p><em>Acanthamoeba</em> are not inhibited in vitro by amphotericin B [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/58\" class=\"abstract_t\">58</a>], although cure with amphotericin B plus rifampicin has been reported in one patient [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/61\" class=\"abstract_t\">61</a>]. Cure using <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> monotherapy has also been described [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/59\" class=\"abstract_t\">59</a>]. The benefit of hyperbaric oxygen is uncertain; its use in combination with <a href=\"topic.htm?path=pentamidine-drug-information\" class=\"drug drug_general\">pentamidine</a> isethionate, miltefosine, <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a>, and <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> was successful in one patient [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/62\" class=\"abstract_t\">62</a>]. Miltefosine is available from the United States Centers for Disease Control and Prevention (CDC) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/63\" class=\"abstract_t\">63</a>].</p><p>Corifungin, a water-soluble polyene, has amebicidal in vitro activity against both the cyst and trophozoite of <em>Acanthamoeba castellanii</em> and may be a promising therapeutic agent [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/64\" class=\"abstract_t\">64</a>].</p><p>Single cerebral lesions should be resected if possible [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/61\" class=\"abstract_t\">61</a>].</p><p class=\"headingAnchor\" id=\"H13571732\"><span class=\"h3\">Balamuthia mandrillaris</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The life cycle is summarized in the figure (<a href=\"image.htm?imageKey=ID%2F77004\" class=\"graphic graphic_figure graphicRef77004 \">figure 3</a>).</p><p class=\"headingAnchor\" id=\"H13571739\"><span class=\"h4\">Epidemiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>B. mandrillaris</em> infection was initially isolated from the brain of a baboon that died of meningoencephalitis at the San Diego Zoo in 1986 [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/65\" class=\"abstract_t\">65</a>]. A serologic test was developed from this isolate and subsequently used to establish a posthumous diagnosis for 16 human cases of meningoencephalitis due to an unknown ameba (including cases from the United States, Mexico, Peru, Venezuela, and Australia).</p><p>The organism was further isolated and identified in 1993 [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/66\" class=\"abstract_t\">66</a>]. Subsequently, about 200 cases have been reported from all continents except from Africa [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/67-70\" class=\"abstract_t\">67-70</a>]. Most cases are reported in the Western hemisphere, with the highest concentration in South America and the United States [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/71-83\" class=\"abstract_t\">71-83</a>].</p><p>In a 2011 review of 35 cases in the United States, most came from the southern states: 15 from California, 6 in Arizona, 6 in Texas, and 3 from Mississippi [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/67\" class=\"abstract_t\">67</a>]. Males were affected 2.5 times more frequently than females, and 55 percent of patients were younger than 15 years old. Subsequently, 9 additional cases of GAE due to <em>Balamuthia</em> have been described in the United States: 3 cases in California plus 1 in Texas, 1 in North Carolina, 1 in Arizona, 1 in Arkansas, 1 in Florida, and 1 in Colorado [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/45,84-91\" class=\"abstract_t\">45,84-91</a>].</p><p>The disease appears to occur more frequently among patients of Hispanic origin; possible explanations include genetic susceptibility or environmental exposure [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/67,92\" class=\"abstract_t\">67,92</a>].</p><p><em>Balamuthia</em> is most commonly isolated from soil [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/93-97\" class=\"abstract_t\">93-97</a>]. In two reports, the ameba has been isolated from environmental sources near patients [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/94,97\" class=\"abstract_t\">94,97</a>]. Infection has been correlated with activities including agricultural exposure, desert motorcycling, dirt biking, swimming, and gardening [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/67\" class=\"abstract_t\">67</a>]. The disease may occur in immunocompetent as well as in immunosuppressed patients. Transmission via organ donation has been described in at least three clusters, including one asymptomatic donor [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/98-100\" class=\"abstract_t\">98-100</a>].</p><p class=\"headingAnchor\" id=\"H13571746\"><span class=\"h4\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Three patterns of clinical presentation have been described: some patients develop an initial skin lesion followed by development of the neurologic manifestations in weeks or months, while others present with CNS involvement. In addition, one case of purely cutaneous <em>Balamuthia </em>infection has been observed [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/101\" class=\"abstract_t\">101</a>].</p><p>Early recognition of the skin lesion may facilitate diagnosis and treatment prior to development of CNS involvement. In some cases, the skin lesion may disappear in the absence of treatment; in such circumstances, subsequent CNS involvement still develops.</p><p>Patients with cutaneous involvement commonly present with a nonulcerated asymptomatic plaque, either single or with occasional satellite lesions (<a href=\"image.htm?imageKey=ID%2F88059\" class=\"graphic graphic_picture graphicRef88059 \">picture 7</a>) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/68,70,102,103\" class=\"abstract_t\">68,70,102,103</a>]. A history of previous trauma can be elicited in many cases. The most common location is the central face over the nose; other locations described are the knee, thigh, chest, and elbow. Occasionally, the border is raised, giving the appearance of an annular lesion. The diameter may be one to several centimeters, and the color may vary from skin toned to slightly red with a violaceous hue. In some cases, the border is ill defined, suggesting soft tissue infiltration. If untreated, tissue infiltration may progress to involve the central face. Sensation is preserved, a sign that permits differentiation from tuberculoid leprosy.</p><p>CNS symptoms are due to thrombotic angiitis, leading to hemorrhage, infarction, and necrosis [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/72\" class=\"abstract_t\">72</a>]. Patients who present with neurologic involvement commonly have fever and malaise [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/67\" class=\"abstract_t\">67</a>]. Initial symptoms may include regression, unilateral headaches, focal seizures, cranial nerve dysfunction, or localized motor deficits [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/71,104\" class=\"abstract_t\">71,104</a>]. Signs of increased intracranial pressure (diffuse headache, nausea, and vomiting) may be present, and later meningeal signs may develop, followed by progressive loss of consciousness (from stupor to coma). This progression generally occurs over 2 to 12 weeks.</p><p class=\"headingAnchor\" id=\"H13571753\"><span class=\"h4\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recognition of the characteristic skin lesion on the central face facilitates early treatment and potential cure of an otherwise fatal disease. The differential diagnosis for cutaneous lesions involving sites other than the face is broader, and a high index of suspicion is required. Common histopathologic characteristics include the presence of a diffuse granulomatous reaction on the reticular dermis in the absence of epidermal changes, ill-defined granulomas, surrounding infiltrate rich in lymphocytes and plasma cells, and abundant multinucleated giant cells inside and outside granulomas (<a href=\"image.htm?imageKey=ID%2F87833\" class=\"graphic graphic_picture graphicRef87833 \">picture 8</a>) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/30\" class=\"abstract_t\">30</a>]. Definitive diagnosis requires visualization of a trophozoite; these are present in 60 to 75 percent of cases and are scarce in number. In addition, trophozoites may be easily confused with histiocytes; visualization of the nucleus and nucleolus of the amoeba may be a distinguishing clue.</p><p>Direct immunofluorescence or immunoperoxidase staining should be performed if possible [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/66,105\" class=\"abstract_t\">66,105</a>]. These are species-specific assays with high sensitivity for detection of the ameba in tissue; they can be performed at the CDC. A PCR technique for detection of amebic DNA material in human tissue has been developed based on a probe consisting of a primer pair from sequence data of the <em>Balamuthia </em>mitochondrial 16S rRNA gene [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/106\" class=\"abstract_t\">106</a>].</p><p>In the setting of CNS involvement, the diagnosis is much more challenging due to a broader differential diagnosis. Clinical clues include a hemorrhagic spinal tap and presence of subacute meningoencephalitis not responding to appropriate antibiotic therapy. CSF may demonstrate lymphocytic pleocytosis with mild to severe elevation of protein concentration and normal to low glucose concentration [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/104\" class=\"abstract_t\">104</a>]. <em>Balamuthia</em> is rarely seen in the CSF. Real-time PCR on CSF can provide results in five hours, although this is not available in many areas [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/23\" class=\"abstract_t\">23</a>]. Metagenomic next-generation sequencing has the potential to be incorporated into the initial workup of encephalitis, even if an amebic origin is unsuspected [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/91\" class=\"abstract_t\">91</a>].</p><p>Imaging of CNS by CT or MRI typically demonstrates multiple lesions ranging from small, solid lesions to large, nodular lesions with ring enhancement (<a href=\"image.htm?imageKey=ID%2F87788\" class=\"graphic graphic_diagnosticimage graphicRef87788 \">image 3</a>) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/107\" class=\"abstract_t\">107</a>]. Intralesional hemorrhage is an important radiological clue.</p><p>Brain biopsy typically demonstrates granulomas with foamy macrophages and multinucleated giant cells accompanied by lymphocytes [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/71,105\" class=\"abstract_t\">71,105</a>]. Amebae have a predilection for location in the vascular walls of capillaries and venules, and vascular damage may be present as tissue hemorrhage. Neutrophils may predominate, and amebas may be seen. Direct immunofluorescence or immunoperoxidase staining should also be performed if possible, as with skin biopsies [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/105\" class=\"abstract_t\">105</a>].</p><p class=\"headingAnchor\" id=\"H13571760\"><span class=\"h4\">Treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal approach to treatment is uncertain; experience is based on a limited number of case reports [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/108-112\" class=\"abstract_t\">108-112</a>]. Treatment with multiple drugs for a prolonged duration is warranted.</p><p>In the United States, six surviving patients have received a combination of <a href=\"topic.htm?path=pentamidine-drug-information\" class=\"drug drug_general\">pentamidine</a>, <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">flucytosine</a>, <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, and a macrolide (<a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> or <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a>) plus any of the following: <a href=\"topic.htm?path=sulfadiazine-drug-information\" class=\"drug drug_general\">sulfadiazine</a>, <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a>, <a href=\"topic.htm?path=thioridazine-drug-information\" class=\"drug drug_general\">thioridazine</a>, or <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/110-112\" class=\"abstract_t\">110-112</a>]. Subsequently, another described a survivor treated with a number of potentially active antimicrobials, making it difficult to determine the role of each one of these drugs or in combination; the last combination included fluconazole, azithromycin, <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a>, and miltefosine [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/84\" class=\"abstract_t\">84</a>].</p><p>In Peru, five surviving patients have been treated with a combination of <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> or <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, in addition to <a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">albendazole</a> and <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/108\" class=\"abstract_t\">108</a>]. Three patients had CNS involvement at the time of presentation, and two had cutaneous involvement only.</p><p>A patient with purely cutaneous <em>Balamuthia </em>infection was treated with <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a>, <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, <a href=\"topic.htm?path=sulfadiazine-drug-information\" class=\"drug drug_general\">sulfadiazine</a>, and a short period of <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/101\" class=\"abstract_t\">101</a>].</p><p>Wide resection of the skin lesion has been used as an additional therapy in some Peruvian cases. A similar approach may be useful for patients with single CNS lesions, followed by medical therapy [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/112\" class=\"abstract_t\">112</a>].</p><p class=\"headingAnchor\" id=\"H13571767\"><span class=\"h3\">Sappinia pedata</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The genus <em>Sappinia</em> comprises two species, <em>S. pedata</em> and <em>S. diploidea</em>. The life cycle of these amebas involves a vegetative trophozoite and a cystic form; animal feces appear to be a necessary component of the life cycle [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/113\" class=\"abstract_t\">113</a>]. A PCR assay can discriminate between the two species of <em>Sappinia</em> and can be incorporated into already-existing multiplex PCR methods to detect <em>Acanthamoeba</em> spp, <em>B. mandrillaris,</em> and <em>N. fowleri</em>, allowing for rapid detection and prompt initiation of therapy [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/114,115\" class=\"abstract_t\">114,115</a>].</p><p>Only one human case of GAE due to <em>Sappinia </em>has been reported (attributed to <em>S. pedata</em>) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/116\" class=\"abstract_t\">116</a>]. The patient was a previously healthy 38-year-old male farmer with no evidence of immunosuppression and who engaged in handling livestock; he presented with headache, vomiting, loss of consciousness, and blurry vision following a sinus infection. A single 2 cm focal lesion located in the posterior left temporal lobe was found and resected. The pathological examination demonstrated trophozoites (40 to 60 microns in diameter) with two nuclei (<a href=\"image.htm?imageKey=ID%2F54458\" class=\"graphic graphic_picture graphicRef54458 \">picture 9</a>). The infection was likely acquired by inhalation [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/116\" class=\"abstract_t\">116</a>].</p><p>The patient was treated with a combination of <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> (250 <span class=\"nowrap\">mg/day</span> for 31 weeks), intravenous <a href=\"topic.htm?path=pentamidine-drug-information\" class=\"drug drug_general\">pentamidine</a> isethionate (300 <span class=\"nowrap\">mg/day</span> for 6 weeks), <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> (200 <span class=\"nowrap\">mg/day),</span> and <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">flucytosine</a> (2.75 g four times a day for 25 weeks) with complete recovery.</p><p class=\"headingAnchor\" id=\"H13571774\"><span class=\"h1\">ACANTHAMOEBA INFECTION OUTSIDE THE CENTRAL NERVOUS SYSTEM</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Acanthamoeba</em> can cause infection outside of the central nervous system (CNS); these include localized infections involving the skin, the nasopharyngeal area, and keratitis. Disseminated infections have also been reported.</p><p class=\"headingAnchor\" id=\"H13571781\"><span class=\"h2\">Cutaneous infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Acanthamoeba</em> cutaneous infection is a rare clinical presentation seen mostly in immunocompromised hosts. It was initially described in an HIV-infected patient, but it has been associated with other immunosuppressive conditions; it has also been reported in healthy hosts [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/56,117,118\" class=\"abstract_t\">56,117,118</a>]. The differential diagnosis is wide and includes viral, mycobacterial, fungal, and bacterial infections.</p><p>One report of five culture-confirmed cases collected over 11 years in a single institution in Peru noted that 80 percent were male, the mean age was 28 years, the clinical course was prolonged (duration of symptoms of approximately four months), and freshwater exposure was noted in two cases [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/118\" class=\"abstract_t\">118</a>]. Three patients were HIV infected, had only cutaneous involvement, and died of opportunistic infections; two patients had no evidence of immunosuppression and developed granulomatous amebic encephalitis (GAE) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/118\" class=\"abstract_t\">118</a>]. Cutaneous lesions began as papules or nodules mostly in the lower limbs and evolved to necrotic ulcers in four patients. Other lesions included infiltrative plaques and cellulitis-like lesions. Lesions may be painful or painless. Pathological examination demonstrated an intense inflammatory reaction in the dermis with histiocyte predominance. Plasmocytes and neutrophils were also present, and <em>Acanthamoeba</em> trophozoites were abundant [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/118\" class=\"abstract_t\">118</a>].</p><p>The optimal approach to treatment of localized cutaneous infections is uncertain. Regimens that have been tried with success include twice-daily applications of topical <a href=\"topic.htm?path=chlorhexidine-gluconate-drug-information\" class=\"drug drug_general\">chlorhexidine</a> gluconate and 2% <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> cream, combined with systemic therapy including intravenous <a href=\"topic.htm?path=pentamidine-drug-information\" class=\"drug drug_general\">pentamidine</a> isethionate, an azole (<a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> or ketoconazole), and <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">flucytosine</a> [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/56,119\" class=\"abstract_t\">56,119</a>]. Other successful combination regimens have included <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a>, flucytosine, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, <a href=\"topic.htm?path=sulfadiazine-drug-information\" class=\"drug drug_general\">sulfadiazine</a> [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/120\" class=\"abstract_t\">120</a>], and <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> plus voriconazole [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/58\" class=\"abstract_t\">58</a>].</p><p class=\"headingAnchor\" id=\"H13571788\"><span class=\"h2\">Nasopharyngeal infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Acanthamoeba</em> infection of the nasal mucosa and paranasal sinuses is a very rare condition that has been described primarily in severely immunosuppressed HIV-infected patients [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/121\" class=\"abstract_t\">121</a>]. The disease is characterized by a chronic course with nasal discharge and sinusitis unresponsive to antimicrobials. Concomitant skin lesions are common [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/121\" class=\"abstract_t\">121</a>]. Findings on the physical examination include purulent nasal secretion, hard brown crusts, and erosion of the nasal septum. Computed tomography (CT) imaging demonstrates mucosal thickening. The diagnosis is established via tissue biopsy stained with hematoxylin-eosin demonstrating a large number of trophozoites.</p><p>Medical treatment has been largely unsuccessful; few patients have responded. Management should consist of surgical excision combined with medical treatment. Drugs that have been administered successfully in one patient include <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">flucytosine</a>, <a href=\"topic.htm?path=pentamidine-drug-information\" class=\"drug drug_general\">pentamidine</a>, amphotericin B, rifampicin, and <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/122\" class=\"abstract_t\">122</a>].</p><p class=\"headingAnchor\" id=\"H13571795\"><span class=\"h2\">Keratitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Acanthamoeba</em> may infect the cornea; keratitis most typically occurs among immunocompetent contact lens wearers who do not adhere to recommended cleaning procedures or as a result of direct inoculation following trauma.</p><p class=\"headingAnchor\" id=\"H13571802\"><span class=\"h3\">Epidemiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The main risk factor for acquiring amebic keratitis is wearing contact lenses for long periods of time. <em>Acanthamoeba</em> has been isolated from contact lens cases, from which it is seeded into the eye, penetrating the corneal stroma and establishing chronic infection [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/28\" class=\"abstract_t\">28</a>]. Use of nonsterile tap water in preparation of contact lens solutions is a well-recognized route of acquisition. In addition, contaminated commercial contact lens solutions have been associated with transmission in the United Kingdom and the United States [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/123,124\" class=\"abstract_t\">123,124</a>]. Factors associated with amebic keratitis include use of recalled contact lens solutions, daily use of soft contact lenses, use of all-in-one (also call multi-purpose) lens solutions, showering while wearing contact lenses, and poor contact lens hygiene [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/125\" class=\"abstract_t\">125</a>].</p><p class=\"headingAnchor\" id=\"H13571809\"><span class=\"h3\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical manifestations include conjunctival hyperemia, tearing, foreign body sensation, pain, and photophobia. Usually a single eye is affected, but bilateral involvement has been observed. Epithelial irregularities and pseudodendritic epithelial lesions are considered early lesions [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/126\" class=\"abstract_t\">126</a>]. Ring-shaped stromal infiltrates are characteristic late-stage lesions of <em>Acanthamoeba </em>keratitis [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H13571816\"><span class=\"h3\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Trophozoites can be visualized via staining of cornea scrapings with fluorescent dye calcofluor [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/127\" class=\"abstract_t\">127</a>]. <em>Acanthamoeba</em> keratitis can also be diagnosed by confocal microscopy [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/128-130\" class=\"abstract_t\">128-130</a>]. Cornea scrapings can be cultured and molecular methods can be applied to differentiate species and quantify the amebic load. In general, polymerase chain reaction (PCR) methods are more sensitive than special stains and cultures [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/131\" class=\"abstract_t\">131</a>]. Corneal biopsies can be cultured and examined microscopically for the presence of trophozoites and cysts. Four genotypes are responsible for most of the infections (T4, T3, T6, and T11) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/132\" class=\"abstract_t\">132</a>].</p><p class=\"headingAnchor\" id=\"H13571823\"><span class=\"h3\">Treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment should be instituted promptly, although the optimal approach is uncertain [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/28,133\" class=\"abstract_t\">28,133</a>]; prolonged infection is a recognized factor for treatment failure. Combination therapy should be administered, including polyhexamethylene biguanide (0.02% PHMB) or biguanide-chlorhexidine in combination with propamidine (0.1%) or hexamidine (0.1%) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/132,134\" class=\"abstract_t\">132,134</a>]. Initially, drops should be applied frequently, with subsequent taper over three to four weeks. Debridement may also be warranted.</p><p>Challenges in treatment of <em>Acanthamoeba</em> keratitis include ameba encystation and development of resistance to medication. Prognostic factors for achieving best visual acuity response include good initial visual acuity, infection related to swimming, absence of epithelial defect, treatment with <a href=\"topic.htm?path=chlorhexidine-gluconate-drug-information\" class=\"drug drug_general\">chlorhexidine</a>, and no receipt of steroids [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/135\" class=\"abstract_t\">135</a>]. Early use of topical steroid prior to initiation of specific antimicrobial therapy has been associated with poorer outcome [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/129\" class=\"abstract_t\">129</a>].</p><p>Chronic refractory cases may require corneal transplantation. Unresponsive cases may require enucleation [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/28\" class=\"abstract_t\">28</a>].</p><p><em>Acanthamoeba</em> keratitis that is associated with an ipsilateral scleritis typically has poor clinical outcomes. Management with <span class=\"nowrap\">anti-inflammatory/immunosuppressive</span> treatment is usually effective in reducing both scleral inflammation and symptoms and possibly reduces the likelihood of enucleation [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/136\" class=\"abstract_t\">136</a>].</p><p class=\"headingAnchor\" id=\"H13571830\"><span class=\"h2\">Disseminated infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Acanthamoeba</em> can cause disseminated infection in immunocompromised hosts [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/1\" class=\"abstract_t\">1</a>]. The skin and lungs are most frequently affected, with or without CNS involvement [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/137\" class=\"abstract_t\">137</a>]. Pulmonary involvement can be bilateral with patchy infiltrates [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/137\" class=\"abstract_t\">137</a>]. The diagnosis is made by observing trophozoites and cysts in tissue samples. This condition is usually diagnosed postmortem. The optimal approach to treatment is uncertain; combination therapy is warranted. (See <a href=\"#H13571725\" class=\"local\">'Treatment'</a> above.)</p><p class=\"headingAnchor\" id=\"H608507245\"><span class=\"h1\">PROTOTHECA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Human protothecosis is an extremely uncommon infectious disease caused by achlorophyllous algae of the family Chlorellaceae, genus <em>Prototheca</em>; it most commonly affects immunocompromised hosts [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/138\" class=\"abstract_t\">138</a>]. The organisms are microscopic single-cell structures that divide asexually by endosporulation and binary fission. Five species are known, of which two affect humans: <em>P. wickerhamii</em> and <em>P. zopfii</em> [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/138,139\" class=\"abstract_t\">138,139</a>]. The pathogenesis is not known.</p><p>Protothecosis is widely distributed across the globe. The algae are found in soil, decaying plants and water, and certain food items, and they also exist as a saprophyte in human skin, nails, and respiratory and digestive tracts [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/140\" class=\"abstract_t\">140</a>]. The organism can infect humans as well as other mammals, such as cows (commonly causing mastitis), deer, dogs, and cats.</p><p class=\"headingAnchor\" id=\"H608506700\"><span class=\"h2\">Epidemiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Protothecosis can be acquired exogenously or, more rarely, endogenously in previously colonized patients. In most cases, the source of infection is exogenous contact with contaminated soil or water, commonly occurring after traumatic inoculation. Infection has also been described as a complication following surgery [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/141,142\" class=\"abstract_t\">141,142</a>].</p><p>Protothecosis occurs most commonly among patients who are immunosuppressed, such as those who are on corticosteroids, have a hematologic malignancy, or have received an organ transplant. Patients who have other chronic underlying conditions (such as diabetes mellitus, alcoholism, or chronic peritoneal dialysis) are also at risk of infection, as are patients with intravascular catheters [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/138,143-145\" class=\"abstract_t\">138,143-145</a>]. Neutrophilic dysfunction increases the risk for infection, although neutropenia does not appear to be an important risk factor [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/138,146\" class=\"abstract_t\">138,146</a>]. HIV infection does not appear to be an important risk factor for protothecosis [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/138,146\" class=\"abstract_t\">138,146</a>].</p><p>In patients with intact immunity, the infection usually follows an indolent clinical course. Individuals whose occupation may predispose to contact with <em>Prototheca</em> species include rice farmers, fisherman, aquarium staff, and handlers of raw seafood [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/138\" class=\"abstract_t\">138</a>]. Most cases are reported in patients &gt;30 years of age, though all ages may be affected.</p><p class=\"headingAnchor\" id=\"H608506836\"><span class=\"h2\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The incubation period for <em>Prototheca</em> infection ranges from 10 days to 4 months. The disease can follow an acute or chronic clinical course and can present as localized or disseminated disease. Three clinical forms are recognized: cutaneous disease, olecranon bursitis, and disseminated disease.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cutaneous disease &ndash; Cutaneous involvement is the most common clinical presentation of protothecosis, accounting for more than half of cases; most occur in association with immunosuppression. The most commonly affected sites include exposed areas such the arms, legs, face, and neck. On the extremities, the infection has a predilection for distal areas such as fingers, wrist, dorsum of the hands, and forearms [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/147,148\" class=\"abstract_t\">147,148</a>].</p><p/><p class=\"bulletIndent1\">The typical manifestation consists of a single vesiculobullous and ulcerative lesion associated with purulent discharge and crusting. A number of other skin lesions have also been described, including translucent papules, erythematous plaques, verrucous plaques, nodules, and abscesses as well as hypopigmented and atrophic lesions (<a href=\"image.htm?imageKey=ID%2F105371\" class=\"graphic graphic_picture graphicRef105371 \">picture 10</a>). A case of an eczematous plaque has been described [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/149\" class=\"abstract_t\">149</a>]. Cutaneous disease usually consists of a single lesion, although cases of multiple lesions have been described. In addition, cases of disseminated disease may be associated with initial cutaneous involvement [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/143\" class=\"abstract_t\">143</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Olecranon bursitis &ndash; Patients with olecranon bursitis due to <em>Prototheca</em> infection are usually immunocompetent, and there is frequently a history of previous trauma to the elbow. The predilection of infection for the olecranon bursa is not fully understood; the association may be explained in part by predisposition of this site to trauma. The clinical course is usually protracted, with symptoms appearing weeks after trauma. Characteristic features include local pain, tenderness, erythema, swelling, and mass formation with serosanguineous discharge [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/139,150,151\" class=\"abstract_t\">139,150,151</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Disseminated disease &ndash; Disseminated disease occurs in association with immunosuppression or catheter use [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/144,145,152,153\" class=\"abstract_t\">144,145,152,153</a>]. Involved organs include the skin, subcutaneous tissues, gastrointestinal tract, peritoneum, blood, and spleen [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/138,139,153,154\" class=\"abstract_t\">138,139,153,154</a>]. Algemia presenting with fever and sepsis syndrome mimicking bacteremia has also been described [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/155\" class=\"abstract_t\">155</a>], as has eosinophilic meningitis [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/156\" class=\"abstract_t\">156</a>].</p><p/><p>In addition to these clinical presentations, tenosynovitis following sclerosing therapy of varicose veins has also been reported [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/142\" class=\"abstract_t\">142</a>].</p><p class=\"headingAnchor\" id=\"H608507072\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of protothecosis should be considered in patients in relevant risk groups, such as those who are immunosuppressed or have an indwelling intravascular catheter, and whose infection (cutaneous disease with suppurative or ulcerative lesions, olecranon bursitis, or disseminated disease) is not responsive to empiric antibacterial therapy.</p><p>The diagnosis of protothecosis is established based on microbiologic tests <span class=\"nowrap\">and/or</span> direct identification in tissue specimens [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/138\" class=\"abstract_t\">138</a>].</p><p>In the microbiology laboratory, <em>Prototheca</em> species can be isolated using a number of different culture media including Sabouraud dextrose agar (incubated at 25 to 35&deg;C), beef infusion broth, blood agar, or brain infusion agar. <em>Prototheca</em> can be aerobic or microaerophilic and usually grow in three to five days; microscopic confirmation using lactophenol cotton blue demonstrates sporangia with endospores. Once isolated in culture, the organism can be identified morphologically via wet slide preparation with calcofluor white, which typically demonstrates sporangia (mother cells; 3 to 30 microns), from which approximately 2 to 20 endospores (9 to 11 microns) develop; the grouping of endospores forms a morula with a characteristic daisy shape (<a href=\"image.htm?imageKey=ID%2F105372\" class=\"graphic graphic_picture graphicRef105372 \">picture 11</a>). <em>P. wickerhamii</em> has more symmetrical morula forms and smaller sporangia than <em>P. zopfii</em> [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/138\" class=\"abstract_t\">138</a>]. Use of matrix-assisted laser desorption ionization&ndash;time of flight mass spectrometry (MALDI-TOF MS) for diagnosis of <em>P. wickerhamii</em> has been described in a case report [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/143\" class=\"abstract_t\">143</a>].</p><p>Skin biopsy typically demonstrates pseudoepitheliomatous hyperplasia with granuloma formation [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/139\" class=\"abstract_t\">139</a>]. The infiltrate may also include a variety of inflammatory cells, including lymphocytes, neutrophils, and eosinophils. Histopathological examination of the bursa demonstrates similar findings, with granuloma formation and predominance of giant cells and plasma cells. <em>Prototheca</em> are not observed readily via hematoxylin-eosin preparations; to enhance their features, special staining procedures such as periodic acid&ndash;Schiff and Gomori methenamine silver stains are needed (<a href=\"image.htm?imageKey=ID%2F105372\" class=\"graphic graphic_picture graphicRef105372 \">picture 11</a>).</p><p class=\"headingAnchor\" id=\"H24936550\"><span class=\"h2\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of protothecosis includes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bacterial infection &ndash; A number of bacterial pathogens may cause cutaneous lesion(s), olecranon bursitis, or systemic infection associated with intravascular catheters. Bacterial infections may be distinguished from protothecosis in that bacteria grow readily with routine culture techniques and generally respond clinically to antibacterial therapy. (See <a href=\"topic.htm?path=clinical-manifestations-of-staphylococcus-aureus-infection-in-adults\" class=\"medical medical_review\">&quot;Clinical manifestations of Staphylococcus aureus infection in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fungal infection (chromoblastomycosis, blastomycosis, cryptococcosis, paracoccidioidomycosis, coccidioidomycosis, and histoplasmosis) &ndash; Fungal pathogens may cause cutaneous lesion(s), olecranon bursitis, or systemic infection, particularly in immunocompromised hosts. Fungal infections are diagnosed via culture <span class=\"nowrap\">and/or</span> histopathology. (See related topics.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tuberculosis &ndash; Tuberculosis may present with extrapulmonary manifestations including cutaneous lesion(s), olecranon bursitis, or disseminated infection. The diagnosis is established via isolation in culture and supported by acid-fast smear <span class=\"nowrap\">and/or</span> histopathology findings. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-miliary-tuberculosis\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and treatment of miliary tuberculosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Mycobacterium marinum</em> infection &ndash; <em>M. marinum</em> is a mycobacterial infection typically associated with soft tissue or joint involvement in the setting of water exposure; the diagnosis is established via isolation in culture and supported by acid-fast smear <span class=\"nowrap\">and/or</span> histopathology findings. (See <a href=\"topic.htm?path=soft-tissue-infections-following-water-exposure#H18\" class=\"medical medical_review\">&quot;Soft tissue infections following water exposure&quot;, section on 'Mycobacterium marinum'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sporotrichosis &ndash; Sporotrichosis is a fungal infection that is typically associated with soft tissue involvement following inoculation of the organism from soil; the diagnosis is established via isolation in culture and supported by histopathology findings. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-sporotrichosis\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of sporotrichosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Leishmaniasis &ndash; Leishmaniasis causes a spectrum of mucocutaneous disease; the diagnosis requires demonstration of the parasite in a clinical specimen by histology, culture, or polymerase chain reaction. (See <a href=\"topic.htm?path=cutaneous-leishmaniasis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Cutaneous leishmaniasis: Clinical manifestations and diagnosis&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H608507120\"><span class=\"h2\">Treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal approach to treatment of protothecosis is uncertain; clinical data are limited, and the rarity of the infection precludes rigorous study.</p><p>In general, management of cutaneous disease should consist of surgical resection (for a single lesion or small number of lesions) <span class=\"nowrap\">and/or</span> debridement (for necrotic ulcerative lesions). Subsequent systemic therapy is warranted for patients with persistent or deep infection. The optimal regimen is uncertain; options for systemic therapy include a combination of intravenous amphotericin B with oral <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/157\" class=\"abstract_t\">157</a>] or an oral therapy with an azole antifungal agent (such as <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, or <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>) [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/138\" class=\"abstract_t\">138</a>]. The optimal duration of therapy is uncertain and should be guided by clinical and microbiologic response; in various reports, the duration of therapy ranges from days to weeks [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/138\" class=\"abstract_t\">138</a>].</p><p>In general, management of olecranon bursitis should consist of bursectomy; failure of serial drainage has been described [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/155\" class=\"abstract_t\">155</a>]. If bursectomy cannot be performed, local instillation of <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> could be performed (1 mg amphotericin B in 1 mL of 5% dextrose in water) weekly for six weeks [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/158,159\" class=\"abstract_t\">158,159</a>]. The optimal subsequent management is uncertain; administration of oral <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, 200 mg once or twice daily, for at least two months is reasonable [<a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/160\" class=\"abstract_t\">160</a>].</p><p>In general, management of disseminated protothecosis consists of intravenous amphotericin B, preferably given as a lipid formulation at a dosage of 3 to 5 <span class=\"nowrap\">mg/kg</span> daily. Intravascular catheters, if present, must be removed. The duration of treatment depends on clinical and microbiological response; typically, weeks of treatment are required.</p><p class=\"headingAnchor\" id=\"H13571956\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Free-living amebas are environmental protozoan parasites with worldwide distribution. Four genera cause disease in humans: <em>Naegleria</em>, <em>Acanthamoeba</em>, <em>Balamuthia</em>, and <em>Sappinia</em>. All these species cause central nervous system (CNS) infections, but several species of <em>Acanthamoeba</em> may cause localized infections outside the CNS (in immunocompetent hosts) or disseminated infections (in immunocompromised hosts). (See <a href=\"#H13571641\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Two CNS clinical syndromes are associated with free-living amebas: primary amebic meningoencephalitis (PAM) caused by <em>Naegleria fowleri</em> and granulomatous amebic encephalitis (GAE) caused by <em>Acanthamoeba </em>spp, <em>Balamuthia mandrillaris,</em> and <em>Sappinia diploidea</em>. (See <a href=\"#H13571648\" class=\"local\">'Central nervous system infections'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary amebic meningoencephalitis is an acute hemorrhagic meningoencephalitis that occurs primarily in immunocompetent hosts; it resembles acute bacterial meningitis both clinically and in laboratory parameters. <em>N. fowleri</em> lives in freshwater environments. Transmission to humans occurs primarily through inhalation of infested water, and activities that increase contact of the nasal mucosa with infested water predispose to infection. The diagnosis is established by visualization of amebas in the cerebrospinal fluid (CSF). Few survivors have been reported; therefore, we favor prompt initiation of amphotericin B (1.5 <span class=\"nowrap\">mg/kg/day)</span> as soon as the diagnosis is considered; adjunctive agents include <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, rifampicin, <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a>, and <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a>. (See <a href=\"#H13571655\" class=\"local\">'Primary amebic meningoencephalitis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Acanthamoeba</em> infection is transmitted via inhalation of cysts through the respiratory tract or by direct skin inoculation followed by hematogenous spread. GAE associated with <em>Acanthamoeba</em> almost exclusively occurs in immunocompromised hosts and is characterized by a subacute clinical presentation. The diagnosis is established by brain biopsy. Few survivors have been reported. The optimal approach to treatment is uncertain; combination regimens are preferred over single-drug regimens. We favor empiric treatment with a combination of <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a>, <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, and <a href=\"topic.htm?path=pentamidine-drug-information\" class=\"drug drug_general\">pentamidine</a> isethionate. <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">Trimethoprim-sulfamethoxazole</a>, <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>, and a macrolide (<a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> or <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a>) can be added to this regimen as well. (See <a href=\"#H13571697\" class=\"local\">'Acanthamoeba'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Balamuthia mandrillaris</em> is transmitted via contact with soil, and infection can occur among immunocompetent hosts. Two patterns of clinical presentation have been described: some patients develop an initial skin lesion followed by development of the neurologic manifestations in weeks or months, while others present with CNS involvement. (See <a href=\"#H13571732\" class=\"local\">'Balamuthia mandrillaris'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Early recognition of the <em>Balamuthia </em>skin lesion may facilitate diagnosis and treatment prior to development of CNS involvement; the lesion consists of an asymptomatic nonulcerated plaque, most commonly on the central face over the nose (<a href=\"image.htm?imageKey=ID%2F88059\" class=\"graphic graphic_picture graphicRef88059 \">picture 7</a>); the second most common location is in the knee area. The skin biopsy usually demonstrates a granulomatous reaction; amebae may be observed and confirmed by immunologic staining or polymerase chain reaction. <em>Balamuthia </em>CNS disease is more difficult to diagnose and has a broader differential diagnosis; brain biopsy may be required. The optimal approach to treatment is uncertain; treatment with multiple drugs for a prolonged duration is warranted. (See <a href=\"#H13571732\" class=\"local\">'Balamuthia mandrillaris'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Acanthamoeba</em> can cause infection outside the CNS; manifestations include cutaneous infection, nasopharyngeal infection, and keratitis. Keratitis usually occurs among immunocompetent contact lens wearers who do not adhere to proper cleaning procedures or as a result of direct inoculation following trauma. Clinical manifestations include conjunctival hyperemia, tearing, foreign body sensation, pain, and photophobia. Combination topical therapy should be administered, including polyhexamethylene biguanide or biguanide-chlorhexidine in combination with propamidine or hexamidine. Debridement may also be warranted. (See <a href=\"#H13571774\" class=\"local\">'Acanthamoeba infection outside the central nervous system'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Human protothecosis is an uncommon infectious disease caused by achlorophyllous algae; it most commonly affects immunocompromised hosts. Clinical manifestations include cutaneous disease, olecranon bursitis, and disseminated disease. The diagnosis is established based on microbiologic tests <span class=\"nowrap\">and/or</span> direct identification in tissue specimens. The optimal approach to treatment is uncertain and consists of antifungal therapy with or without surgery. (See <a href=\"#H608507245\" class=\"local\">'Prototheca'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H5756541\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Dr. Karin Leder, who contributed to earlier versions of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/1\" class=\"nounderline abstract_t\">Schuster FL, Visvesvara GS. Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. Int J Parasitol 2004; 34:1001.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/2\" class=\"nounderline abstract_t\">Visvesvara GS, Moura H, Schuster FL. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol 2007; 50:1.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/3\" class=\"nounderline abstract_t\">Qvarnstrom Y, da Silva AJ, Schuster FL, et al. Molecular confirmation of Sappinia pedata as a causative agent of amoebic encephalitis. J Infect Dis 2009; 199:1139.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/4\" class=\"nounderline abstract_t\">Visvesvara GS. Free-living amebae as opportunist agents of human disease. J Neuroparasitol 2010; 1:1.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/5\" class=\"nounderline abstract_t\">Trabelsi H, Dendana F, Sellami A, et al. Pathogenic free-living amoebae: epidemiology and clinical review. Pathol Biol (Paris) 2012; 60:399.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/6\" class=\"nounderline abstract_t\">Johnson RO, Cope JR, Moskowitz M, et al. Notes from the Field: Primary Amebic Meningoencephalitis Associated with Exposure to Swimming Pool Water Supplied by an Overland Pipe - Inyo County, California, 2015. MMWR Morb Mortal Wkly Rep 2016; 65:424.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/7\" class=\"nounderline abstract_t\">Cope JR, Murphy J, Kahler A, et al. Primary Amebic Meningoencephalitis Associated With Rafting on an Artificial Whitewater River: Case Report and Environmental Investigation. Clin Infect Dis 2018; 66:548.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/8\" class=\"nounderline abstract_t\">Booth PJ, Bodager D, Slade TA, Jett S. Primary Amebic Meningoencephalitis Associated with Hot Spring Exposure During International Travel - Seminole County, Florida, July 2014. MMWR Morb Mortal Wkly Rep 2015; 64:1226.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/9\" class=\"nounderline abstract_t\">Wellings FM, Amuso PT, Chang SL, Lewis AL. Isolation and identification of pathogenic Naegleria from Florida lakes. Appl Environ Microbiol 1977; 34:661.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/10\" class=\"nounderline abstract_t\">Cope JR, Ratard RC, Hill VR, et al. The first association of a primary amebic meningoencephalitis death with culturable Naegleria fowleri in tap water from a US treated public drinking water system. Clin Infect Dis 2015; 60:e36.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/11\" class=\"nounderline abstract_t\">Shakoor S, Beg MA, Mahmood SF, et al. Primary amebic meningoencephalitis caused by Naegleria fowleri, Karachi, Pakistan. Emerg Infect Dis 2011; 17:258.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/12\" class=\"nounderline abstract_t\">Yoder JS, Straif-Bourgeois S, Roy SL, et al. Primary amebic meningoencephalitis deaths associated with sinus irrigation using contaminated tap water. Clin Infect Dis 2012; 55:e79.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/13\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Notes from the field: primary amebic meningoencephalitis associated with ritual nasal rinsing--St. Thomas, U.S. Virgin islands, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:903.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/14\" class=\"nounderline abstract_t\">Ugonabo JA, Gugnani HC. Nasal carriage of Naegleria fowleri and its environmental occurrence in Borno State, Nigeria. J Commun Dis 1989; 21:111.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/15\" class=\"nounderline abstract_t\">Kemble SK, Lynfield R, DeVries AS, et al. Fatal Naegleria fowleri infection acquired in Minnesota: possible expanded range of a deadly thermophilic organism. Clin Infect Dis 2012; 54:805.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/16\" class=\"nounderline abstract_t\">Yoder JS, Eddy BA, Visvesvara GS, et al. The epidemiology of primary amoebic meningoencephalitis in the USA, 1962-2008. Epidemiol Infect 2010; 138:968.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/17\" class=\"nounderline abstract_t\">Marciano-Cabral F, Cline ML, Bradley SG. Specificity of antibodies from human sera for Naegleria species. J Clin Microbiol 1987; 25:692.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/18\" class=\"nounderline abstract_t\">Cursons RT, Brown TJ, Keys EA, et al. Immunity to pathogenic free-living amoebae: role of humoral antibody. Infect Immun 1980; 29:401.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/19\" class=\"nounderline abstract_t\">Wellings FM. Amoebic meningoencephalitis. J Fla Med Assoc 1977; 64:327.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/20\" class=\"nounderline abstract_t\">Hannafin B, LoVecchio F, Rosenberg D. Update on emerging infections: News from the Centers for Disease Control and Prevention. Primary amebic meningoencephalitis-Arizona, Florida, and Texas, 2007. Ann Emerg Med 2009; 54:469.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/21\" class=\"nounderline abstract_t\">Roy SL, Metzger R, Chen JG, et al. Risk for transmission of Naegleria fowleri from solid organ transplantation. Am J Transplant 2014; 14:163.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/22\" class=\"nounderline abstract_t\">Capewell LG, Harris AM, Yoder JS, et al. Diagnosis, Clinical Course, and Treatment of Primary Amoebic Meningoencephalitis in the United States, 1937-2013. J Pediatric Infect Dis Soc 2015; 4:e68.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/23\" class=\"nounderline abstract_t\">Qvarnstrom Y, Visvesvara GS, Sriram R, da Silva AJ. Multiplex real-time PCR assay for simultaneous detection of Acanthamoeba spp., Balamuthia mandrillaris, and Naegleria fowleri. J Clin Microbiol 2006; 44:3589.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/24\" class=\"nounderline abstract_t\">Singh P, Kochhar R, Vashishta RK, et al. Amebic meningoencephalitis: spectrum of imaging findings. AJNR Am J Neuroradiol 2006; 27:1217.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/25\" class=\"nounderline abstract_t\">Ma P, Visvesvara GS, Martinez AJ, et al. Naegleria and Acanthamoeba infections: review. Rev Infect Dis 1990; 12:490.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/26\" class=\"nounderline abstract_t\">Cervantes-Sandoval I, Serrano-Luna Jde J, Garc&iacute;a-Latorre E, et al. Characterization of brain inflammation during primary amoebic meningoencephalitis. Parasitol Int 2008; 57:307.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/27\" class=\"nounderline abstract_t\">Lopez C, Budge P, Chen J, et al. Primary amebic meningoencephalitis: a case report and literature review. Pediatr Emerg Care 2012; 28:272.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/28\" class=\"nounderline abstract_t\">Schuster FL, Visvesvara GS. Opportunistic amoebae: challenges in prophylaxis and treatment. Drug Resist Updat 2004; 7:41.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/29\" class=\"nounderline abstract_t\">Seidel JS, Harmatz P, Visvesvara GS, et al. Successful treatment of primary amebic meningoencephalitis. N Engl J Med 1982; 306:346.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/30\" class=\"nounderline abstract_t\">Vargas-Zepeda J, G&oacute;mez-Alcal&aacute; AV, V&aacute;squez-Morales JA, et al. Successful treatment of Naegleria fowleri meningoencephalitis by using intravenous amphotericin B, fluconazole and rifampicin. Arch Med Res 2005; 36:83.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/31\" class=\"nounderline abstract_t\">Linam WM, Ahmed M, Cope JR, et al. Successful treatment of an adolescent with Naegleria fowleri primary amebic meningoencephalitis. Pediatrics 2015; 135:e744.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/32\" class=\"nounderline abstract_t\">Duma RJ, Rosenblum WI, McGehee RF, et al. Primary amoebic meningoencephalitis caused by Naegleria. Two new cases, response to amphotericin B, and a review. Ann Intern Med 1971; 74:923.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/33\" class=\"nounderline abstract_t\">Goswick SM, Brenner GM. Activities of therapeutic agents against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. J Parasitol 2003; 89:837.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/34\" class=\"nounderline abstract_t\">Goswick SM, Brenner GM. Activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. Antimicrob Agents Chemother 2003; 47:524.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/35\" class=\"nounderline abstract_t\">Grace E, Asbill S, Virga K. Naegleria fowleri: pathogenesis, diagnosis, and treatment options. Antimicrob Agents Chemother 2015; 59:6677.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/36\" class=\"nounderline abstract_t\">Gautam PL, Sharma S, Puri S, et al. A rare case of survival from primary amebic meningoencephalitis. Indian J Crit Care Med 2012; 16:34.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/37\" class=\"nounderline abstract_t\">Yadav D, Aneja S, Dutta R, et al. Youngest survivor of naegleria meningitis. Indian J Pediatr 2013; 80:253.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/38\" class=\"nounderline abstract_t\">Cope JR, Conrad DA, Cohen N, et al. Use of the Novel Therapeutic Agent Miltefosine for the Treatment of Primary Amebic Meningoencephalitis: Report of 1 Fatal and 1 Surviving Case. Clin Infect Dis 2016; 62:774.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/39\" class=\"nounderline abstract_t\">Soltow SM, Brenner GM. Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. Antimicrob Agents Chemother 2007; 51:23.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/40\" class=\"nounderline abstract_t\">Akpek G, Uslu A, Huebner T, et al. Granulomatous amebic encephalitis: an under-recognized cause of infectious mortality after hematopoietic stem cell transplantation. Transpl Infect Dis 2011; 13:366.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/41\" class=\"nounderline abstract_t\">Satlin MJ, Graham JK, Visvesvara GS, et al. Fulminant and fatal encephalitis caused by Acanthamoeba in a kidney transplant recipient: case report and literature review. Transpl Infect Dis 2013; 15:619.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/42\" class=\"nounderline abstract_t\">Reddy R, Vijayasaradhi M, Uppin MS, et al. Acanthamoeba meningoencephalitis in an immunocompetent patient: an autopsy case report. Neuropathology 2011; 31:183.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/43\" class=\"nounderline abstract_t\">Walochnik J, Aichelburg A, Assadian O, et al. Granulomatous amoebic encephalitis caused by Acanthamoeba amoebae of genotype T2 in a human immunodeficiency virus-negative patient. J Clin Microbiol 2008; 46:338.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/44\" class=\"nounderline abstract_t\">Booton GC, Visvesvara GS, Byers TJ, et al. Identification and distribution of Acanthamoeba species genotypes associated with nonkeratitis infections. J Clin Microbiol 2005; 43:1689.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/45\" class=\"nounderline abstract_t\">Pietrucha-Dilanchian P, Chan JC, Castellano-Sanchez A, et al. Balamuthia mandrillaris and Acanthamoeba amebic encephalitis with neurotoxoplasmosis coinfection in a patient with advanced HIV infection. J Clin Microbiol 2012; 50:1128.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/46\" class=\"nounderline abstract_t\">Marciano-Cabral F, Cabral G. Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev 2003; 16:273.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/47\" class=\"nounderline abstract_t\">Petry F, Torzewski M, Bohl J, et al. Early diagnosis of Acanthamoeba infection during routine cytological examination of cerebrospinal fluid. J Clin Microbiol 2006; 44:1903.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/48\" class=\"nounderline abstract_t\">Visvesvara GS, Mirra SS, Brandt FH, et al. Isolation of two strains of Acanthamoeba castellanii from human tissue and their pathogenicity and isoenzyme profiles. J Clin Microbiol 1983; 18:1405.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/49\" class=\"nounderline abstract_t\">Khan NA. Acanthamoeba: biology and increasing importance in human health. FEMS Microbiol Rev 2006; 30:564.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/50\" class=\"nounderline abstract_t\">MacLean RC, Hafez N, Tripathi S, et al. Identification of Acanthamoeba sp. in paraffin-embedded CNS tissue from an HIV+ individual by PCR. Diagn Microbiol Infect Dis 2007; 57:289.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/51\" class=\"nounderline abstract_t\">Khan NA. Acanthamoeba and the blood-brain barrier: the breakthrough. J Med Microbiol 2008; 57:1051.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/52\" class=\"nounderline abstract_t\">Mayer PL, Larkin JA, Hennessy JM. Amebic encephalitis. Surg Neurol Int 2011; 2:50.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/53\" class=\"nounderline abstract_t\">Duma RJ, Finley R. In vitro susceptibility of pathogenic Naegleria and Acanthamoeba speicies to a variety of therapeutic agents. Antimicrob Agents Chemother 1976; 10:370.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/54\" class=\"nounderline abstract_t\">Stevens AR, Willaert E. Drug sensitivity and resistance of four Acanthamoeba species. Trans R Soc Trop Med Hyg 1980; 74:806.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/55\" class=\"nounderline abstract_t\">Ferrante A, Rowan-Kelly B, Thong YH. In vitro sensitivity of virulent Acanthamoeba culbertsoni to a variety of drugs and antibiotics. Int J Parasitol 1984; 14:53.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/56\" class=\"nounderline abstract_t\">Slater CA, Sickel JZ, Visvesvara GS, et al. Brief report: successful treatment of disseminated acanthamoeba infection in an immunocompromised patient. N Engl J Med 1994; 331:85.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/57\" class=\"nounderline abstract_t\">Seijo Martinez M, Gonzalez-Mediero G, Santiago P, et al. Granulomatous amebic encephalitis in a patient with AIDS: isolation of acanthamoeba sp. Group II from brain tissue and successful treatment with sulfadiazine and fluconazole. J Clin Microbiol 2000; 38:3892.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/58\" class=\"nounderline abstract_t\">Walia R, Montoya JG, Visvesvera GS, et al. A case of successful treatment of cutaneous Acanthamoeba infection in a lung transplant recipient. Transpl Infect Dis 2007; 9:51.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/59\" class=\"nounderline abstract_t\">Aichelburg AC, Walochnik J, Assadian O, et al. Successful treatment of disseminated Acanthamoeba sp. infection with miltefosine. Emerg Infect Dis 2008; 14:1743.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/60\" class=\"nounderline abstract_t\">Lackner P, Beer R, Broessner G, et al. Acute granulomatous acanthamoeba encephalitis in an immunocompetent patient. Neurocrit Care 2010; 12:91.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/61\" class=\"nounderline abstract_t\">Sheng WH, Hung CC, Huang HH, et al. First case of granulomatous amebic encephalitis caused by Acanthamoeba castellanii in Taiwan. Am J Trop Med Hyg 2009; 81:277.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/62\" class=\"nounderline abstract_t\">Maritschnegg P, Sovinz P, Lackner H, et al. Granulomatous amebic encephalitis in a child with acute lymphoblastic leukemia successfully treated with multimodal antimicrobial therapy and hyperbaric oxygen. J Clin Microbiol 2011; 49:446.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Parasites &mdash; Naegleria fowleri &mdash; Primary Amebic Meningoencephalitis (PAM) &mdash; Amebic Encephalitis: Treatment. http://www.cdc.gov/parasites/naegleria/treatment-hcp.html (Accessed on August 21, 2013).</li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/64\" class=\"nounderline abstract_t\">Debnath A, Tunac JB, Silva-Olivares A, et al. In vitro efficacy of corifungin against Acanthamoeba castellanii trophozoites and cysts. Antimicrob Agents Chemother 2014; 58:1523.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/65\" class=\"nounderline abstract_t\">Visvesvara GS, Martinez AJ, Schuster FL, et al. Leptomyxid ameba, a new agent of amebic meningoencephalitis in humans and animals. J Clin Microbiol 1990; 28:2750.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/66\" class=\"nounderline abstract_t\">Visvesvara GS, Schuster FL, Martinez AJ. Balamuthia mandrillaris, N. G., N. Sp., agent of amebic meningoencephalitis in humans and other animals. J Eukaryot Microbiol 1993; 40:504.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/67\" class=\"nounderline abstract_t\">Diaz JH. The public health threat from Balamuthia mandrillaris in the southern United States. J La State Med Soc 2011; 163:197.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/68\" class=\"nounderline abstract_t\">Reed RP, Cooke-Yarborough CM, Jaquiery AL, et al. Fatal granulomatous amoebic encephalitis caused by Balamuthia mandrillaris. Med J Aust 1997; 167:82.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/69\" class=\"nounderline abstract_t\">Kodet R, Noh&yacute;nkov&aacute; E, Tich&yacute; M, et al. Amebic encephalitis caused by Balamuthia mandrillaris in a Czech child: description of the first case from Europe. Pathol Res Pract 1998; 194:423.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/70\" class=\"nounderline abstract_t\">Sangruchi T, Martinez AJ, Visvesvara GS. Spontaneous granulomatous amebic encephalitis: report of four cases from Thailand. Southeast Asian J Trop Med Public Health 1994; 25:309.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/71\" class=\"nounderline abstract_t\">Campos P, Cabrera J, Gotuzzo E, Guill&eacute;n D. [Neurological involvement in free living amebiasis]. Rev Neurol 1999; 29:316.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/72\" class=\"nounderline abstract_t\">Recavarren-Arce S, Velarde C, Gotuzzo E, Cabrera J. Amoeba angeitic lesions of the central nervous system in Balamuthia mandrilaris amoebiasis. Hum Pathol 1999; 30:269.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/73\" class=\"nounderline abstract_t\">Galarza C, Larrea P, Kumakawa H. Amebiasis Cut&aacute;nea de Vida libre. Primer caso reportado en el Hospital Dos de Mayo, Lima, Per&uacute;. Dermatolog&iacute;a Peruana 1997; 7:65.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/74\" class=\"nounderline abstract_t\">Ballona R, Aquije M. Compromiso cut&aacute;neo en encefalitis granulomatosa  amebiana fatal causada por Balamuthia mandrillaris. Folia Dermatologica Peruana 2003; 14:28.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/75\" class=\"nounderline abstract_t\">Taratuto AL, Monges J, Acefe JC, et al. Leptomyxid amoeba encephalitis: report of the first case in Argentina. Trans R Soc Trop Med Hyg 1991; 85:77.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/76\" class=\"nounderline abstract_t\">Galarza M, Cuccia V, Sosa FP, Monges JA. Pediatric granulomatous cerebral amebiasis: a delayed diagnosis. Pediatr Neurol 2002; 26:153.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/77\" class=\"nounderline abstract_t\">Mart&iacute;nez AJ, Guerra AE, Garc&iacute;a-Tamayo J, et al. Granulomatous amebic encephalitis: a review and report of a spontaneous case from Venezuela. Acta Neuropathol 1994; 87:430.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/78\" class=\"nounderline abstract_t\">Gonz&aacute;lez-Alfonzo JE, Mart&iacute;nez AJ, Garc&iacute;a V, et al. Granulomatous encephalitis due to a leptomyxid amoeba. Trans R Soc Trop Med Hyg 1991; 85:480.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/79\" class=\"nounderline abstract_t\">Riestra-Castaneda JM, Riestra-Castaneda R, Gonzalez-Garrido AA, et al. Granulomatous amebic encephalitis due to Balamuthia mandrillaris (Leptomyxiidae): report of four cases from Mexico. Am J Trop Med Hyg 1997; 56:603.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/80\" class=\"nounderline abstract_t\">Chimelli L, Hahn MD, Scaravilli F, et al. Granulomatous amoebic encephalitis due to leptomyxid amoebae: report of the first Brazilian case. Trans R Soc Trop Med Hyg 1992; 86:635.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/81\" class=\"nounderline abstract_t\">Silva-Vergara ML, Da Cunha Colombo ER, De Figueiredo Vissotto E, et al. Disseminated Balamuthia mandrillaris amoeba infection in an AIDS patient from Brazil. Am J Trop Med Hyg 2007; 77:1096.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/82\" class=\"nounderline abstract_t\">Cuevas P M, Smoje P G, Jofr&eacute; M L, et al. [Granulomatous amoebic meningoencephalitis by Balamuthia mandrillaris: case report and literature review]. Rev Chilena Infectol 2006; 23:237.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/83\" class=\"nounderline abstract_t\">Odd&oacute; B D, Ciani A S, Vial C P. [Granulomatous amebic encephalitis caused by Balamuthia mandrillaris. First case diagnosed in Chile]. Rev Chilena Infectol 2006; 23:232.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/84\" class=\"nounderline abstract_t\">Vollmer ME, Glaser C. A Balamuthia survivor. JMM Case Rep 2016; 3:e005031.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/85\" class=\"nounderline abstract_t\">Lehmer L, Ulibarri G, Ragsdale B, et al. Cutaneous Balamuthia mandrillaris infection as a precursor to Balamuthia amoebic encephalitis (BAE) in a healthy 84-year-old Californian. Dermatol Online J 2017; 23:4.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/86\" class=\"nounderline abstract_t\">Wilson MR, Shanbhag NM, Reid MJ, et al. Diagnosing Balamuthia mandrillaris Encephalitis With Metagenomic Deep Sequencing. Ann Neurol 2015; 78:722.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/87\" class=\"nounderline abstract_t\">Roy SL, Atkins JT, Gennuso R, et al. Assessment of blood-brain barrier penetration of miltefosine used to treat a fatal case of granulomatous amebic encephalitis possibly caused by an unusual Balamuthia mandrillaris strain. Parasitol Res 2015; 114:4431.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/88\" class=\"nounderline abstract_t\">Schafer KR, Shah N, Almira-Suarez MI, et al. Disseminated Balamuthia mandrillaris Infection. J Clin Microbiol 2015; 53:3072.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/89\" class=\"nounderline abstract_t\">Phillips BC, Gokden M, Petersen E. Granulomatous encephalitis due to Balamuthia mandrillaris is not limited to immune-compromised patients. Clin Neurol Neurosurg 2013; 115:1102.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/90\" class=\"nounderline abstract_t\">Stidd DA, Root B, Weinand ME, Anton R. Granulomatous amoebic encephalitis caused by Balamuthia mandrillaris in an immunocompetent girl. World Neurosurg 2012; 78:715.e7.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/91\" class=\"nounderline abstract_t\">Greninger AL, Messacar K, Dunnebacke T, et al. Clinical metagenomic identification of Balamuthia mandrillaris encephalitis and assembly of the draft genome: the continuing case for reference genome sequencing. Genome Med 2015; 7:113.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/92\" class=\"nounderline abstract_t\">Schuster FL, Glaser C, Honarmand S, et al. Balamuthia amebic encephalitis risk, Hispanic Americans. Emerg Infect Dis 2004; 10:1510.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/93\" class=\"nounderline abstract_t\">Niyyati M, Lorenzo-Morales J, Rezaeian M, et al. Isolation of Balamuthia mandrillaris from urban dust, free of known infectious involvement. Parasitol Res 2009; 106:279.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/94\" class=\"nounderline abstract_t\">Dunnebacke TH, Schuster FL, Yagi S, Booton GC. Balamuthia mandrillaris from soil samples. Microbiology 2004; 150:2837.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/95\" class=\"nounderline abstract_t\">Ahmad AF, Andrew PW, Kilvington S. Development of a nested PCR for environmental detection of the pathogenic free-living amoeba Balamuthia mandrillaris. J Eukaryot Microbiol 2011; 58:269.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/96\" class=\"nounderline abstract_t\">Schuster FL, Dunnebacke TH, Booton GC, et al. Environmental isolation of Balamuthia mandrillaris associated with a case of amebic encephalitis. J Clin Microbiol 2003; 41:3175.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/97\" class=\"nounderline abstract_t\">Cabello-V&iacute;lchez AM, Reyes-Batlle M, Montalb&aacute;n-Sandoval E, et al. The isolation of Balamuthia mandrillaris from environmental sources from Peru. Parasitol Res 2014; 113:2509.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/98\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Notes from the field: transplant-transmitted Balamuthia mandrillaris --- Arizona, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1182.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/99\" class=\"nounderline abstract_t\">Gupte AA, Hocevar SN, Lea AS, et al. Transmission of Balamuthia mandrillaris through solid organ transplantation: utility of organ recipient serology to guide clinical management. Am J Transplant 2014; 14:1417.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/100\" class=\"nounderline abstract_t\">Farnon EC, Kokko KE, Budge PJ, et al. Transmission of Balamuthia mandrillaris by Organ Transplantation. Clin Infect Dis 2016; 63:878.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/101\" class=\"nounderline abstract_t\">Chang OH, Liu F, Knopp E, et al. Centrofacial Balamuthiasis: case report of a rare cutaneous amebic infection. J Cutan Pathol 2016; 43:892.</a></li><li class=\"breakAll\">Bravo FG, Cabrera J, Gotuzzo E, et al. Cutaneous manifestations of infection by free living amebas, with special emphasis on Balamuthia mandrillaris. In: Tropical Dermatology, Tyring SK, Lupi O, Henage UR (Eds), 2005. p.49.</li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/103\" class=\"nounderline abstract_t\">Pritzker AS, Kim BK, Agrawal D, et al. Fatal granulomatous amebic encephalitis caused by Balamuthia mandrillaris presenting as a skin lesion. J Am Acad Dermatol 2004; 50:S38.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/104\" class=\"nounderline abstract_t\">Schuster FL, Yagi S, Gavali S, et al. Under the radar: balamuthia amebic encephalitis. Clin Infect Dis 2009; 48:879.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/105\" class=\"nounderline abstract_t\">Guarner J, Bartlett J, Shieh WJ, et al. Histopathologic spectrum and immunohistochemical diagnosis of amebic meningoencephalitis. Mod Pathol 2007; 20:1230.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/106\" class=\"nounderline abstract_t\">Yagi S, Schuster FL, Visvesvara GS. Demonstration of Balamuthia and Acanthamoeba mitochondrial DNA in sectioned archival brain and other tissues by the polymerase chain reaction. Parasitol Res 2008; 102:211.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/107\" class=\"nounderline abstract_t\">Healy JF. Balamuthia amebic encephalitis: radiographic and pathologic findings. AJNR Am J Neuroradiol 2002; 23:486.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/108\" class=\"nounderline abstract_t\">Mart&iacute;nez DY, Seas C, Bravo F, et al. Successful treatment of Balamuthia mandrillaris amoebic infection with extensive neurological and cutaneous involvement. Clin Infect Dis 2010; 51:e7.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/109\" class=\"nounderline abstract_t\">Schuster FL, Guglielmo BJ, Visvesvara GS. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J Eukaryot Microbiol 2006; 53:121.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/110\" class=\"nounderline abstract_t\">Cary LC, Maul E, Potter C, et al. Balamuthia mandrillaris meningoencephalitis: survival of a pediatric patient. Pediatrics 2010; 125:e699.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/111\" class=\"nounderline abstract_t\">Doyle JS, Campbell E, Fuller A, et al. Balamuthia mandrillaris brain abscess successfully treated with complete surgical excision and prolonged combination antimicrobial therapy. J Neurosurg 2011; 114:458.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/112\" class=\"nounderline abstract_t\">Orozco L, Hanigan W, Khan M, et al. Neurosurgical intervention in the diagnosis and treatment of Balamuthia mandrillaris encephalitis. J Neurosurg 2011; 115:636.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/113\" class=\"nounderline abstract_t\">Walochnik J, Wylezich C, Michel R. The genus Sappinia: history, phylogeny and medical relevance. Exp Parasitol 2010; 126:4.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/114\" class=\"nounderline abstract_t\">De Jonckheere JF. Origin and evolution of the worldwide distributed pathogenic amoeboflagellate Naegleria fowleri. Infect Genet Evol 2011; 11:1520.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/115\" class=\"nounderline abstract_t\">Marciano-Cabral F. Free-living amoebae as agents of human infection. J Infect Dis 2009; 199:1104.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/116\" class=\"nounderline abstract_t\">Gelman BB, Rauf SJ, Nader R, et al. Amoebic encephalitis due to Sappinia diploidea. JAMA 2001; 285:2450.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/117\" class=\"nounderline abstract_t\">Gonzalez MM, Gould E, Dickinson G, et al. Acquired immunodeficiency syndrome associated with Acanthamoeba infection and other opportunistic organisms. Arch Pathol Lab Med 1986; 110:749.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/118\" class=\"nounderline abstract_t\">Galarza C, Ramos W, Gutierrez EL, et al. Cutaneous acanthamebiasis infection in immunocompetent and immunocompromised patients. Int J Dermatol 2009; 48:1324.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/119\" class=\"nounderline abstract_t\">Helton J, Loveless M, White CR Jr. Cutaneous acanthamoeba infection associated with leukocytoclastic vasculitis in an AIDS patient. Am J Dermatopathol 1993; 15:146.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/120\" class=\"nounderline abstract_t\">Gee SN, Rothschild B, Click J, et al. Tender ulceronecrotic nodules in a patient with leukemia. Cutaneous acanthamebiasis. Arch Dermatol 2011; 147:857.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/121\" class=\"nounderline abstract_t\">Dunand VA, Hammer SM, Rossi R, et al. Parasitic sinusitis and otitis in patients infected with human immunodeficiency virus: report of five cases and review. Clin Infect Dis 1997; 25:267.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/122\" class=\"nounderline abstract_t\">Rivera MA, Padhya TA. Acanthamoeba: a rare primary cause of rhinosinusitis. Laryngoscope 2002; 112:1201.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/123\" class=\"nounderline abstract_t\">Jasim H, Knox-Cartwright N, Cook S, Tole D. Increase in acanthamoeba keratitis may be associated with use of multipurpose contact lens solution. BMJ 2012; 344:e1246.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/124\" class=\"nounderline abstract_t\">Verani JR, Lorick SA, Yoder JS, et al. National outbreak of Acanthamoeba keratitis associated with use of a contact lens solution, United States. Emerg Infect Dis 2009; 15:1236.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/125\" class=\"nounderline abstract_t\">Fraser MN, Wong Q, Shah L, et al. Characteristics of an Acanthamoeba keratitis outbreak in British Columbia between 2003 and 2007. Ophthalmology 2012; 119:1120.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/126\" class=\"nounderline abstract_t\">Mannis MJ, Tamaru R, Roth AM, et al. Acanthamoeba sclerokeratitis. Determining diagnostic criteria. Arch Ophthalmol 1986; 104:1313.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/127\" class=\"nounderline abstract_t\">Wilhelmus KR, Osato MS, Font RL, et al. Rapid diagnosis of Acanthamoeba keratitis using calcofluor white. Arch Ophthalmol 1986; 104:1309.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/128\" class=\"nounderline abstract_t\">Kumar RL, Cruzat A, Hamrah P. Current state of in vivo confocal microscopy in management of microbial keratitis. Semin Ophthalmol 2010; 25:166.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/129\" class=\"nounderline abstract_t\">Robaei D, Carnt N, Minassian DC, Dart JK. The impact of topical corticosteroid use before diagnosis on the outcome of Acanthamoeba keratitis. Ophthalmology 2014; 121:1383.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/130\" class=\"nounderline abstract_t\">Page MA, Mathers WD. Acanthamoeba keratitis: a 12-year experience covering a wide spectrum of presentations, diagnoses, and outcomes. J Ophthalmol 2013; 2013:670242.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/131\" class=\"nounderline abstract_t\">Ikeda Y, Miyazaki D, Yakura K, et al. Assessment of real-time polymerase chain reaction detection of Acanthamoeba and prognosis determinants of Acanthamoeba keratitis. Ophthalmology 2012; 119:1111.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/132\" class=\"nounderline abstract_t\">Seal DV. Acanthamoeba keratitis update-incidence, molecular epidemiology and new drugs for treatment. Eye (Lond) 2003; 17:893.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/133\" class=\"nounderline abstract_t\">Alkharashi M, Lindsley K, Law HA, Sikder S. Medical interventions for acanthamoeba keratitis. Cochrane Database Syst Rev 2015; :CD010792.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/134\" class=\"nounderline abstract_t\">Lim N, Goh D, Bunce C, et al. Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. Am J Ophthalmol 2008; 145:130.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/135\" class=\"nounderline abstract_t\">Kaiserman I, Bahar I, McAllum P, et al. Prognostic factors in Acanthamoeba keratitis. Can J Ophthalmol 2012; 47:312.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/136\" class=\"nounderline abstract_t\">Iovieno A, Gore DM, Carnt N, Dart JK. Acanthamoeba sclerokeratitis: epidemiology, clinical features, and treatment outcomes. Ophthalmology 2014; 121:2340.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/137\" class=\"nounderline abstract_t\">Kaul DR, Lowe L, Visvesvara GS, et al. Acanthamoeba infection in a patient with chronic graft-versus-host disease occurring during treatment with voriconazole. Transpl Infect Dis 2008; 10:437.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/138\" class=\"nounderline abstract_t\">Lass-Fl&ouml;rl C, Mayr A. Human protothecosis. Clin Microbiol Rev 2007; 20:230.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/139\" class=\"nounderline abstract_t\">Mayorga J, Barba-G&oacute;mez JF, Verduzco-Mart&iacute;nez AP, et al. Protothecosis. Clin Dermatol 2012; 30:432.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/140\" class=\"nounderline abstract_t\">Tello-Zavala MC, Mercado-Lara A, G&oacute;mez-Hern&aacute;ndez N, Recio-Martinez V. Disseminated protothecosis in a Mexican child. Pediatr Infect Dis J 2013; 32:e476.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/141\" class=\"nounderline abstract_t\">Sirikulchayanonta V, Visuthikosol V, Tanphaichitra D, Prajaktham R. Protothecosis following hand injury. A case report. J Hand Surg Br 1989; 14:88.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/142\" class=\"nounderline abstract_t\">Lee JS, Moon GH, Lee NY, Peck KR. Case report: protothecal tenosynovitis. Clin Orthop Relat Res 2008; 466:3143.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/143\" class=\"nounderline abstract_t\">Bandaranayake TD, Paniz Mondolfi A, Peaper DR, Malinis MF. Prototheca wickerhamii algaemia: an emerging infection in solid organ transplant recipients. Transpl Infect Dis 2015; 17:599.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/144\" class=\"nounderline abstract_t\">Gaur S, Marrin C, Barnes RA. Disseminated protothecosis following traumatic Hickman line removal in a patient with leukaemia. Med Mycol 2010; 48:410.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/145\" class=\"nounderline abstract_t\">P&eacute;rez Mel&oacute;n C, Camba M, Tinajas A, et al. [Prototheca Wickerhami peritonitis in patients on peritoneal dialysis]. Nefrologia 2007; 27:81.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/146\" class=\"nounderline abstract_t\">Zhang QQ, Li L, Zhu LP, et al. Cutaneous protothecosis in patient with diabetes mellitus and review of published case reports. Mycopathologia 2012; 173:163.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/147\" class=\"nounderline abstract_t\">Hillesheim PB, Bahrami S. Cutaneous protothecosis. Arch Pathol Lab Med 2011; 135:941.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/148\" class=\"nounderline abstract_t\">Seok JY, Lee Y, Lee H, et al. Human cutaneous protothecosis: report of a case and literature review. Korean J Pathol 2013; 47:575.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/149\" class=\"nounderline abstract_t\">Zhang Q, Li L, Yuli K, et al. A case of cutaneous protothecosis mimics eczema. Mycopathologia 2015; 179:163.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/150\" class=\"nounderline abstract_t\">Knox J, Coloe SV, Perera C, et al. Prototheca wickerhamii olecranon bursitis successfully treated with adjunctive systemic itraconazole. Pathology 2015; 47:388.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/151\" class=\"nounderline abstract_t\">Pednekar M, Chandra PA, Margulis Y, et al. Protothecal olecranon bursitis: an unusual algal infection. Am J Med Sci 2011; 342:424.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/152\" class=\"nounderline abstract_t\">Fong K, Tee SI, Ho MS, Pan JY. Cutaneous protothecosis in a patient with previously undiagnosed HIV infection. Australas J Dermatol 2015; 56:e71.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/153\" class=\"nounderline abstract_t\">Laeng RH, Egger C, Schaffner T, et al. Protothecosis in an HIV-positive patient. Am J Surg Pathol 1994; 18:1261.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/154\" class=\"nounderline abstract_t\">Murata M, Ito T, Nagae K, et al. Disseminated protothecosis manifesting with multiple, rapidly-progressing skin ulcers: successful treatment with amphotericin B. Eur J Dermatol 2015; 25:208.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/155\" class=\"nounderline abstract_t\">Torres HA, Bodey GP, Tarrand JJ, Kontoyiannis DP. Protothecosis in patients with cancer: case series and literature review. Clin Microbiol Infect 2003; 9:786.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/156\" class=\"nounderline abstract_t\">Ahn A, Choe YJ, Chang J, et al. Chronic Eosinophilic Meningoencephalitis by Prototheca Wickerhamii in an Immunocompetent Boy. Pediatr Infect Dis J 2017; 36:687.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/157\" class=\"nounderline abstract_t\">Boyd AS, Langley M, King LE Jr. Cutaneous manifestations of Prototheca infections. J Am Acad Dermatol 1995; 32:758.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/158\" class=\"nounderline abstract_t\">Cochran RK, Pierson CL, Sell TL, Palella T. Protothecal olecranon bursitis: treatment with intrabursal amphotericin B. Rev Infect Dis 1986; 8:952.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/159\" class=\"nounderline abstract_t\">Van den Bossche D, de Haan R, Van der Werff Ten Bosch J, et al. Case report: Infrapatellar bursitis caused by Prototheca wickerhamii. Med Mycol Case Rep 2012; 1:13.</a></li><li><a href=\"https://www.uptodate.com/contents/free-living-amebas-and-prototheca/abstract/160\" class=\"nounderline abstract_t\">Kantrow SM, Boyd AS. Protothecosis. Dermatol Clin 2003; 21:249.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5687 Version 30.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H13571956\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H13571641\" id=\"outline-link-H13571641\">INTRODUCTION</a></li><li><a href=\"#H13571648\" id=\"outline-link-H13571648\">CENTRAL NERVOUS SYSTEM INFECTIONS</a><ul><li><a href=\"#H13571655\" id=\"outline-link-H13571655\">Primary amebic meningoencephalitis</a><ul><li><a href=\"#H4971137\" id=\"outline-link-H4971137\">- Naegleria fowleri</a><ul><li><a href=\"#H13571662\" id=\"outline-link-H13571662\">Epidemiology</a></li><li><a href=\"#H13571669\" id=\"outline-link-H13571669\">Clinical manifestations</a></li><li><a href=\"#H13571676\" id=\"outline-link-H13571676\">Diagnosis</a></li><li><a href=\"#H1746433426\" id=\"outline-link-H1746433426\">Differential diagnosis</a></li><li><a href=\"#H13571683\" id=\"outline-link-H13571683\">Treatment</a></li></ul></li></ul></li><li><a href=\"#H13571690\" id=\"outline-link-H13571690\">Granulomatous amebic encephalitis</a><ul><li><a href=\"#H13571697\" id=\"outline-link-H13571697\">- Acanthamoeba</a><ul><li><a href=\"#H13571704\" id=\"outline-link-H13571704\">Epidemiology</a></li><li><a href=\"#H13571711\" id=\"outline-link-H13571711\">Clinical manifestations</a></li><li><a href=\"#H3212527470\" id=\"outline-link-H3212527470\">Diagnosis</a></li><li><a href=\"#H1746433471\" id=\"outline-link-H1746433471\">Differential diagnosis</a></li><li><a href=\"#H13571725\" id=\"outline-link-H13571725\">Treatment</a></li></ul></li><li><a href=\"#H13571732\" id=\"outline-link-H13571732\">- Balamuthia mandrillaris</a><ul><li><a href=\"#H13571739\" id=\"outline-link-H13571739\">Epidemiology</a></li><li><a href=\"#H13571746\" id=\"outline-link-H13571746\">Clinical manifestations</a></li><li><a href=\"#H13571753\" id=\"outline-link-H13571753\">Diagnosis</a></li><li><a href=\"#H13571760\" id=\"outline-link-H13571760\">Treatment</a></li></ul></li><li><a href=\"#H13571767\" id=\"outline-link-H13571767\">- Sappinia pedata</a></li></ul></li></ul></li><li><a href=\"#H13571774\" id=\"outline-link-H13571774\">ACANTHAMOEBA INFECTION OUTSIDE THE CENTRAL NERVOUS SYSTEM</a><ul><li><a href=\"#H13571781\" id=\"outline-link-H13571781\">Cutaneous infection</a></li><li><a href=\"#H13571788\" id=\"outline-link-H13571788\">Nasopharyngeal infection</a></li><li><a href=\"#H13571795\" id=\"outline-link-H13571795\">Keratitis</a><ul><li><a href=\"#H13571802\" id=\"outline-link-H13571802\">- Epidemiology</a></li><li><a href=\"#H13571809\" id=\"outline-link-H13571809\">- Clinical manifestations</a></li><li><a href=\"#H13571816\" id=\"outline-link-H13571816\">- Diagnosis</a></li><li><a href=\"#H13571823\" id=\"outline-link-H13571823\">- Treatment</a></li></ul></li><li><a href=\"#H13571830\" id=\"outline-link-H13571830\">Disseminated infection</a></li></ul></li><li><a href=\"#H608507245\" id=\"outline-link-H608507245\">PROTOTHECA</a><ul><li><a href=\"#H608506700\" id=\"outline-link-H608506700\">Epidemiology</a></li><li><a href=\"#H608506836\" id=\"outline-link-H608506836\">Clinical manifestations</a></li><li><a href=\"#H608507072\" id=\"outline-link-H608507072\">Diagnosis</a></li><li><a href=\"#H24936550\" id=\"outline-link-H24936550\">Differential diagnosis</a></li><li><a href=\"#H608507120\" id=\"outline-link-H608507120\">Treatment</a></li></ul></li><li><a href=\"#H13571956\" id=\"outline-link-H13571956\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H5756541\" id=\"outline-link-H5756541\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/5687|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=ID/87779\" class=\"graphic graphic_diagnosticimage\">- CT imaging of a patient with PAM</a></li><li><a href=\"image.htm?imageKey=RADIOL/85823\" class=\"graphic graphic_diagnosticimage\">- MRI amebic encephalitis due to Balamuthia mandrillaris</a></li><li><a href=\"image.htm?imageKey=ID/87788\" class=\"graphic graphic_diagnosticimage\">- Radiologic imaging in Balamuthia mandrillaris amebic infection</a></li></ul></li><li><div id=\"ID/5687|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/53111\" class=\"graphic graphic_figure\">- Naegleria life cycle</a></li><li><a href=\"image.htm?imageKey=ID/70542\" class=\"graphic graphic_figure\">- Acanthamoeba life cycle</a></li><li><a href=\"image.htm?imageKey=ID/77004\" class=\"graphic graphic_figure\">- Balamuthia life cycle</a></li></ul></li><li><div id=\"ID/5687|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/87778\" class=\"graphic graphic_picture\">- Trophozoites of Naegleria fowleri</a></li><li><a href=\"image.htm?imageKey=ID/58751\" class=\"graphic graphic_picture\">- Naegleria fowleri trophozoite</a></li><li><a href=\"image.htm?imageKey=GAST/87780\" class=\"graphic graphic_picture\">- Pathological findings in PAM</a></li><li><a href=\"image.htm?imageKey=ID/64215\" class=\"graphic graphic_picture\">- Acanthamoeba trophozoites</a></li><li><a href=\"image.htm?imageKey=ID/87781\" class=\"graphic graphic_picture\">- Cyst of Acanthamoeba in brain tissue</a></li><li><a href=\"image.htm?imageKey=ID/88021\" class=\"graphic graphic_picture\">- Pathologic findings in GAE</a></li><li><a href=\"image.htm?imageKey=ID/88059\" class=\"graphic graphic_picture\">- Balamuthia skin lesions </a></li><li><a href=\"image.htm?imageKey=ID/87833\" class=\"graphic graphic_picture\">- Pathological findings in B mandrillaris amebic infection</a></li><li><a href=\"image.htm?imageKey=ID/54458\" class=\"graphic graphic_picture\">- Sappinia trophozoites</a></li><li><a href=\"image.htm?imageKey=ID/105371\" class=\"graphic graphic_picture\">- Cutaneous protothecosis</a></li><li><a href=\"image.htm?imageKey=ID/105372\" class=\"graphic graphic_picture\">- Protothecosis skin biopsy</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=central-nervous-system-tuberculosis\" class=\"medical medical_review\">Central nervous system tuberculosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-acute-bacterial-meningitis-in-adults\" class=\"medical medical_review\">Clinical features and diagnosis of acute bacterial meningitis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-sporotrichosis\" class=\"medical medical_review\">Clinical features and diagnosis of sporotrichosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-nocardiosis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of nocardiosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-staphylococcus-aureus-infection-in-adults\" class=\"medical medical_review\">Clinical manifestations of Staphylococcus aureus infection in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-miliary-tuberculosis\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and treatment of miliary tuberculosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-pathologic-features-and-diagnosis-of-primary-central-nervous-system-lymphoma\" class=\"medical medical_review\">Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-leishmaniasis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Cutaneous leishmaniasis: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cysticercosis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Cysticercosis: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-treatment-of-disseminated-histoplasmosis-in-hiv-uninfected-patients\" class=\"medical medical_review\">Diagnosis and treatment of disseminated histoplasmosis in HIV-uninfected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-clinical-manifestations-of-invasive-aspergillosis\" class=\"medical medical_review\">Epidemiology and clinical manifestations of invasive aspergillosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-infected-patients\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-brain-abscess\" class=\"medical medical_review\">Pathogenesis, clinical manifestations, and diagnosis of brain abscess</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=soft-tissue-infections-following-water-exposure\" class=\"medical medical_review\">Soft tissue infections following water exposure</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=toxoplasmosis-in-hiv-infected-patients\" class=\"medical medical_review\">Toxoplasmosis in HIV-infected patients</a></li></ul></div></div>","javascript":null}